OA16358A - Co-crystals and salts of CCR3-inhibitors. - Google Patents
Co-crystals and salts of CCR3-inhibitors. Download PDFInfo
- Publication number
- OA16358A OA16358A OA1201300132 OA16358A OA 16358 A OA16358 A OA 16358A OA 1201300132 OA1201300132 OA 1201300132 OA 16358 A OA16358 A OA 16358A
- Authority
- OA
- OAPI
- Prior art keywords
- alkyl
- formula
- acid
- compounds
- crystals
- Prior art date
Links
- 239000011780 sodium chloride Substances 0.000 title claims abstract description 47
- 150000003839 salts Chemical class 0.000 title claims abstract description 44
- 239000003112 inhibitor Substances 0.000 title abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 106
- 239000002253 acid Substances 0.000 claims description 27
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 22
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 22
- 206010020751 Hypersensitivity Diseases 0.000 claims description 21
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 20
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 206010064930 Age-related macular degeneration Diseases 0.000 claims description 16
- 208000002780 Macular Degeneration Diseases 0.000 claims description 16
- NTBIYBAYFBNTCD-UHFFFAOYSA-N dibenzoyl 2,3-dihydroxybutanedioate Chemical compound C=1C=CC=CC=1C(=O)OC(=O)C(O)C(O)C(=O)OC(=O)C1=CC=CC=C1 NTBIYBAYFBNTCD-UHFFFAOYSA-N 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 125000004430 oxygen atoms Chemical group O* 0.000 claims description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 11
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 claims description 11
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 11
- 239000011664 nicotinic acid Substances 0.000 claims description 11
- 229960003512 nicotinic acid Drugs 0.000 claims description 11
- 235000001968 nicotinic acid Nutrition 0.000 claims description 11
- QIAFMBKCNZACKA-UHFFFAOYSA-N Hippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims description 10
- VFQXVTODMYMSMJ-UHFFFAOYSA-N Isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 claims description 10
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 10
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 10
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 10
- 235000010323 ascorbic acid Nutrition 0.000 claims description 10
- 239000011668 ascorbic acid Substances 0.000 claims description 10
- 229960005070 ascorbic acid Drugs 0.000 claims description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 229960003966 nicotinamide Drugs 0.000 claims description 10
- 235000005152 nicotinamide Nutrition 0.000 claims description 10
- 239000011570 nicotinamide Substances 0.000 claims description 10
- 208000006673 Asthma Diseases 0.000 claims description 9
- 150000001450 anions Chemical group 0.000 claims description 9
- 230000002757 inflammatory Effects 0.000 claims description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 8
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 8
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- DSLZVSRJTYRBFB-ZNIBRBMXSA-N L-mannaric acid Chemical compound OC(=O)[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-ZNIBRBMXSA-N 0.000 claims description 6
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 6
- 201000001320 atherosclerosis Diseases 0.000 claims description 6
- 230000001363 autoimmune Effects 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 230000002458 infectious Effects 0.000 claims description 6
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 5
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 claims description 5
- BHQCQFFYRZLCQQ-OELDTZBJSA-N Cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 5
- 239000004380 Cholic acid Substances 0.000 claims description 5
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 5
- KXGVEGMKQFWNSR-LLQZFEROSA-N Deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- 235000019766 L-Lysine Nutrition 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims description 5
- ODHCTXKNWHHXJC-VKHMYHEASA-N Pyroglutamic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 5
- 229940081974 Saccharin Drugs 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- 229940035893 Uracil Drugs 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- 244000052616 bacterial pathogens Species 0.000 claims description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 5
- 229960002471 cholic acid Drugs 0.000 claims description 5
- 235000019416 cholic acid Nutrition 0.000 claims description 5
- 229960003964 deoxycholic acid Drugs 0.000 claims description 5
- 230000004957 immunoregulator effect Effects 0.000 claims description 5
- 229960003646 lysine Drugs 0.000 claims description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 claims description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims description 5
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 claims description 5
- 230000001717 pathogenic Effects 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 5
- 235000019204 saccharin Nutrition 0.000 claims description 5
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 5
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 5
- 229960001860 salicylate Drugs 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 5
- 229940095064 tartrate Drugs 0.000 claims description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- ODHCTXKNWHHXJC-GSVOUGTGSA-N 5-oxo-D-proline Chemical compound OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims description 4
- 229940050390 Benzoate Drugs 0.000 claims description 4
- 229940001468 Citrate Drugs 0.000 claims description 4
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 4
- 235000014852 L-arginine Nutrition 0.000 claims description 4
- 239000002211 L-ascorbic acid Substances 0.000 claims description 4
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 claims description 4
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 4
- 229960005010 Orotic Acid Drugs 0.000 claims description 4
- PXQPEWDEAKTCGB-UHFFFAOYSA-N Orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 4
- 229960002429 Proline Drugs 0.000 claims description 4
- 229960004274 Stearic acid Drugs 0.000 claims description 4
- 201000011190 diabetic macular edema Diseases 0.000 claims description 4
- 229940050411 fumarate Drugs 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- 229940086735 succinate Drugs 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 150000003840 hydrochlorides Chemical class 0.000 claims description 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 30
- 101700070842 CCR3 Proteins 0.000 abstract description 21
- 102100005861 CCR3 Human genes 0.000 abstract description 21
- 102000004499 CCR3 Receptors Human genes 0.000 abstract description 11
- 108010017316 CCR3 Receptors Proteins 0.000 abstract description 11
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 79
- 239000000243 solution Substances 0.000 description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- -1 ΜΙΡ-la Proteins 0.000 description 42
- 238000004128 high performance liquid chromatography Methods 0.000 description 38
- 239000000543 intermediate Substances 0.000 description 38
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 239000000126 substance Substances 0.000 description 36
- 239000005557 antagonist Substances 0.000 description 34
- 230000003042 antagnostic Effects 0.000 description 30
- 102000009410 chemokine receptors Human genes 0.000 description 26
- 108050000299 chemokine receptors Proteins 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 25
- 210000004027 cells Anatomy 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 235000019439 ethyl acetate Nutrition 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 230000027455 binding Effects 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 239000007832 Na2SO4 Substances 0.000 description 15
- 238000004166 bioassay Methods 0.000 description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- 230000002194 synthesizing Effects 0.000 description 14
- 239000000843 powder Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 108090001123 antibodies Proteins 0.000 description 12
- 102000004965 antibodies Human genes 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 230000000051 modifying Effects 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 239000012267 brine Substances 0.000 description 11
- 230000002829 reduced Effects 0.000 description 11
- 229960001375 Lactose Drugs 0.000 description 10
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 239000008101 lactose Substances 0.000 description 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 150000002829 nitrogen Chemical group 0.000 description 9
- 239000003380 propellant Substances 0.000 description 9
- 239000000377 silicon dioxide Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 101710043203 P23p89 Proteins 0.000 description 8
- JKEKMBGUVUKMQB-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JKEKMBGUVUKMQB-UHFFFAOYSA-N 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102100016449 CCL5 Human genes 0.000 description 7
- 102100016450 CCL7 Human genes 0.000 description 7
- 101700044004 CCL7 Proteins 0.000 description 7
- 108010055166 Chemokine CCL5 Proteins 0.000 description 7
- JMUPMJGUKXYCMF-UHFFFAOYSA-N N-[2-[2-[[6-[5-acetamido-6-(5-acetamido-1,2,4-trihydroxy-6-oxohexan-3-yl)oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-[3-[3-acetamido-4-hydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymet Chemical compound OC1C(NC(C)=O)C(OC(C(O)C(C=O)NC(=O)C)C(O)CO)OC(CO)C1OC1C(O)C(OC2C(C(O)C(O)C(CO)O2)OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)NC(C)=O)C(O)C(COC2C(C(O)C(O)C(CO)O2)OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)NC(C)=O)O1 JMUPMJGUKXYCMF-UHFFFAOYSA-N 0.000 description 7
- 101700019351 TRYM Proteins 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 102100019485 CCL13 Human genes 0.000 description 6
- 101700034979 CCL13 Proteins 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 6
- 210000003979 Eosinophils Anatomy 0.000 description 6
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 6
- 208000006897 Interstitial Lung Disease Diseases 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 201000004624 dermatitis Diseases 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 238000000634 powder X-ray diffraction Methods 0.000 description 6
- 230000002335 preservative Effects 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 102100008428 CCL2 Human genes 0.000 description 5
- 101700006000 CCL2 Proteins 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 108010012236 Chemokines Proteins 0.000 description 5
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 5
- 229960001334 Corticosteroids Drugs 0.000 description 5
- 206010029113 Neovascularisation Diseases 0.000 description 5
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000009610 hypersensitivity Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000002932 luster Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229940037001 sodium edetate Drugs 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 5
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 102000001902 CC Chemokines Human genes 0.000 description 4
- 108010040471 CC Chemokines Proteins 0.000 description 4
- 102100019487 CCL11 Human genes 0.000 description 4
- 102100016451 CCL8 Human genes 0.000 description 4
- 101700045693 CCL8 Proteins 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 108010082548 Chemokine CCL11 Proteins 0.000 description 4
- 108091006011 G proteins Proteins 0.000 description 4
- 102000003688 G-protein coupled receptors Human genes 0.000 description 4
- 108090000045 G-protein coupled receptors Proteins 0.000 description 4
- 102000030007 GTP-Binding Proteins Human genes 0.000 description 4
- 108091000058 GTP-Binding Proteins Proteins 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000000111 anti-oxidant Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 231100000406 dermatitis Toxicity 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 235000011167 hydrochloric acid Nutrition 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 201000004681 psoriasis Diseases 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- IKVDXUFZJARKPF-UHFFFAOYSA-M zinc;cyclopropane;bromide Chemical compound Br[Zn+].C1C[CH-]1 IKVDXUFZJARKPF-UHFFFAOYSA-M 0.000 description 4
- 229940022663 Acetate Drugs 0.000 description 3
- 229940006211 Anticholinergic mydriatics and cycloplegics Drugs 0.000 description 3
- 229940065524 Anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 3
- 210000003651 Basophils Anatomy 0.000 description 3
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 101700043583 CCR5 Proteins 0.000 description 3
- 102100012080 CCR5 Human genes 0.000 description 3
- 101700029727 CCR8 Proteins 0.000 description 3
- 102100008148 CCR8 Human genes 0.000 description 3
- 229960005069 Calcium Drugs 0.000 description 3
- 229960003563 Calcium Carbonate Drugs 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010016228 Fasciitis Diseases 0.000 description 3
- 229960001031 Glucose Drugs 0.000 description 3
- 229940093915 Gynecological Organic acids Drugs 0.000 description 3
- 210000000265 Leukocytes Anatomy 0.000 description 3
- AEUKDPKXTPNBNY-XEYRWQBLSA-N MCP 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 3
- 235000019759 Maize starch Nutrition 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 208000005987 Polymyositis Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-Lymphocytes Anatomy 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000002015 acyclic group Chemical group 0.000 description 3
- 239000000808 adrenergic beta-agonist Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 3
- 230000001078 anti-cholinergic Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000003454 betamimetic Effects 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 239000008139 complexing agent Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- XGHFPTMUVIDZNF-UHFFFAOYSA-N methyl 2,6-dibromopyridine-4-carboxylate Chemical compound COC(=O)C1=CC(Br)=NC(Br)=C1 XGHFPTMUVIDZNF-UHFFFAOYSA-N 0.000 description 3
- XXFVJWCKNWSTCY-UHFFFAOYSA-N methyl 2-amino-6-methylpyridine-4-carboxylate Chemical compound COC(=O)C1=CC(C)=NC(N)=C1 XXFVJWCKNWSTCY-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- WSVLPVUVIUVCRA-RJMJUYIDSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-RJMJUYIDSA-N 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-Methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 2
- BARJEOMVLKJPRB-UHFFFAOYSA-N 2-amino-6-methylpyridine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC(N)=N1 BARJEOMVLKJPRB-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical class OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- 206010058284 Allergy to arthropod sting Diseases 0.000 description 2
- 108009000283 Allograft Rejection Proteins 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 2
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 description 2
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 2
- 108010093579 Arachidonate 5-Lipoxygenase Proteins 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 description 2
- 206010003816 Autoimmune disease Diseases 0.000 description 2
- 208000009137 Behcet Syndrome Diseases 0.000 description 2
- 201000008335 Behcet's disease Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N Benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N Bis(trimethylsilyl)amine Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102100019494 CCL17 Human genes 0.000 description 2
- 101700084100 CCL17 Proteins 0.000 description 2
- 102100012030 CCL24 Human genes 0.000 description 2
- 101700019063 CCR6 Proteins 0.000 description 2
- 102100008133 CCR6 Human genes 0.000 description 2
- 102100008151 CCR7 Human genes 0.000 description 2
- 102000019388 CXC chemokine Human genes 0.000 description 2
- 108050006947 CXC chemokine Proteins 0.000 description 2
- 108090000426 Caspase 1 Proteins 0.000 description 2
- 101700032207 Ccl12 Proteins 0.000 description 2
- 210000000170 Cell Membrane Anatomy 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- 108010083647 Chemokine CCL24 Proteins 0.000 description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
- CSGQJHQYWJLPKY-UHFFFAOYSA-N Citrazinic acid Chemical compound OC(=O)C=1C=C(O)NC(=O)C=1 CSGQJHQYWJLPKY-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000010247 Contact Dermatitis Diseases 0.000 description 2
- 206010011401 Crohn's disease Diseases 0.000 description 2
- 206010011686 Cutaneous vasculitis Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical class C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 206010013700 Drug hypersensitivity Diseases 0.000 description 2
- 229940121647 EGFR inhibitors Drugs 0.000 description 2
- 208000005679 Eczema Diseases 0.000 description 2
- 206010014952 Eosinophilia myalgia syndrome Diseases 0.000 description 2
- 206010053776 Eosinophilic cellulitis Diseases 0.000 description 2
- 208000006916 Eosinophilic synovitis Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 206010018620 Goodpasture's syndrome Diseases 0.000 description 2
- 206010018651 Graft versus host disease Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000003964 Histone deacetylases Human genes 0.000 description 2
- 108090000353 Histone deacetylases Proteins 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- HAEJPQIATWHALX-KQYNXXCUSA-N Inosine triphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-N 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N Interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 Interleukin-8 Drugs 0.000 description 2
- 229960001021 Lactose Monohydrate Drugs 0.000 description 2
- 206010024377 Leukocytoclastic vasculitis Diseases 0.000 description 2
- 201000009324 Loeffler syndrome Diseases 0.000 description 2
- 208000009856 Lung Disease Diseases 0.000 description 2
- 101700083887 MAPK1 Proteins 0.000 description 2
- 102100016823 MAPK1 Human genes 0.000 description 2
- 101700036258 MECOM Proteins 0.000 description 2
- 210000002540 Macrophages Anatomy 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- 210000000138 Mast Cells Anatomy 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010028417 Myasthenia gravis Diseases 0.000 description 2
- 210000000440 Neutrophils Anatomy 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 102100007288 PTGDR2 Human genes 0.000 description 2
- 101710013017 PTGDR2 Proteins 0.000 description 2
- 229940049954 Penicillin Drugs 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010037162 Psoriatic arthropathy Diseases 0.000 description 2
- 210000001525 Retina Anatomy 0.000 description 2
- 206010038932 Retinopathy Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 206010039083 Rhinitis Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 206010040767 Sjogren's syndrome Diseases 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 208000006641 Skin Disease Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 208000006045 Spondylarthropathy Diseases 0.000 description 2
- 206010052775 Spondyloarthropathy Diseases 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229960004793 Sucrose Drugs 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- 206010046736 Urticarias Diseases 0.000 description 2
- 229940029983 VITAMINS Drugs 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 206010047124 Vasculitis necrotising Diseases 0.000 description 2
- 208000004762 Vasculitis, Leukocytoclastic, Cutaneous Diseases 0.000 description 2
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 229960000626 benzylpenicillin Drugs 0.000 description 2
- 201000004569 blindness Diseases 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000003399 chemotactic Effects 0.000 description 2
- 150000001805 chlorine compounds Chemical group 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 231100000080 dermatitis contact Toxicity 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 231100001003 eczema Toxicity 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019264 food flavour enhancer Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 2
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 201000002481 myositis Diseases 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101700050775 oct-1 Proteins 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 201000001263 psoriatic arthritis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000000241 respiratory Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 239000001187 sodium carbonate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 201000009594 systemic scleroderma Diseases 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000002689 toll-like receptors Human genes 0.000 description 2
- 108020000411 toll-like receptors Proteins 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 201000006704 ulcerative colitis Diseases 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamins Natural products 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NDZYPHLNJZSQJY-QNWVGRARSA-N 1-(5-acetyl-4-methyl-1,3-thiazol-2-yl)-3-[(1R,2S)-2-[[(3S)-3-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]cyclohexyl]urea Chemical compound CC1=C(C(=O)C)SC(NC(=O)N[C@H]2[C@@H](CCCC2)CN2C[C@H](CC=3C=CC(F)=CC=3)CCC2)=N1 NDZYPHLNJZSQJY-QNWVGRARSA-N 0.000 description 1
- BNINSXCMJBCDPZ-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)-2-methylbenzene Chemical compound CC1=CC(CCl)=CC=C1Cl BNINSXCMJBCDPZ-UHFFFAOYSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- QLMUMHYEALQXDG-UHFFFAOYSA-N 2-amino-N,N,6-trimethylpyridine-4-carboxamide Chemical compound CN(C)C(=O)C1=CC(C)=NC(N)=C1 QLMUMHYEALQXDG-UHFFFAOYSA-N 0.000 description 1
- MSWQBBSWODQKLQ-UHFFFAOYSA-M 2-bromo-6-methoxypyridine-4-carboxylate Chemical compound COC1=CC(C([O-])=O)=CC(Br)=N1 MSWQBBSWODQKLQ-UHFFFAOYSA-M 0.000 description 1
- ZGZMEKHQIZSZOH-UHFFFAOYSA-N 2-chloro-6-methylpyridine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC(Cl)=N1 ZGZMEKHQIZSZOH-UHFFFAOYSA-N 0.000 description 1
- REUUQOIBNWISSI-UHFFFAOYSA-N 4-(bromomethyl)-1-chloro-2-methylbenzene Chemical compound CC1=CC(CBr)=CC=C1Cl REUUQOIBNWISSI-UHFFFAOYSA-N 0.000 description 1
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-Piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- 239000003406 5-lipoxygenase-activating protein inhibitor Substances 0.000 description 1
- 101710026914 AAG Proteins 0.000 description 1
- 101710024119 ABCC4 Proteins 0.000 description 1
- 102100006348 ABCC4 Human genes 0.000 description 1
- 102100016908 ACKR1 Human genes 0.000 description 1
- 101700040666 ACKR2 Proteins 0.000 description 1
- 102100016910 ACKR2 Human genes 0.000 description 1
- 101700073545 ACKR4 Proteins 0.000 description 1
- 102000025609 ACKR4 Human genes 0.000 description 1
- 102100000269 AIMP2 Human genes 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N Acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 102000017910 Adrenergic receptor family Human genes 0.000 description 1
- 108060003345 Adrenergic receptor family Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 240000007109 Arundinaria gigantea Species 0.000 description 1
- 210000001130 Astrocytes Anatomy 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N BINAP Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 108060001001 BRK1 Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N Bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 102000017483 C chemokine Human genes 0.000 description 1
- 108050005711 C chemokine Proteins 0.000 description 1
- 101700017623 CALCA Proteins 0.000 description 1
- 101700041770 CALCR Proteins 0.000 description 1
- 102100006374 CASP1 Human genes 0.000 description 1
- 102100012032 CCL20 Human genes 0.000 description 1
- 101700018681 CCL20 Proteins 0.000 description 1
- 102100008431 CCL26 Human genes 0.000 description 1
- 101700083927 CCR1 Proteins 0.000 description 1
- 102100005860 CCR1 Human genes 0.000 description 1
- 101700024466 CCR10 Proteins 0.000 description 1
- 102100000148 CCR10 Human genes 0.000 description 1
- 102100005862 CCR2 Human genes 0.000 description 1
- 101700024589 CCR4 Proteins 0.000 description 1
- 102100003247 CCR4 Human genes 0.000 description 1
- 101700076302 CCR9 Proteins 0.000 description 1
- 101700026482 CCRL2 Proteins 0.000 description 1
- 108060001945 CRK Proteins 0.000 description 1
- 108060001122 CRTISO Proteins 0.000 description 1
- 101710003734 CXCR4 Proteins 0.000 description 1
- 102100002212 CXCR4 Human genes 0.000 description 1
- 101710025651 CXCR5 Proteins 0.000 description 1
- 102100002072 CXCR5 Human genes 0.000 description 1
- 101700060333 CXCR6 Proteins 0.000 description 1
- 102100002068 CXCR6 Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229960001927 Cetylpyridinium Chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M Cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 108010083698 Chemokine CCL26 Proteins 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229940109248 Cromoglycate Drugs 0.000 description 1
- 229940109275 Cyclamate Drugs 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 210000004443 Dendritic Cells Anatomy 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N Diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 229940052760 Dopamine agonists Drugs 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 208000004332 Evans Syndrome Diseases 0.000 description 1
- 102100011848 FPR2 Human genes 0.000 description 1
- 101710017954 FPR2 Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- 229960002598 Fumaric acid Drugs 0.000 description 1
- 102000027732 GABAA receptors Human genes 0.000 description 1
- 108091008003 GABAA receptors Proteins 0.000 description 1
- 101710008404 GAPDH Proteins 0.000 description 1
- 201000004779 Graves' disease Diseases 0.000 description 1
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical group C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 101710045394 HTR2A Proteins 0.000 description 1
- 101710045397 HTR2C Proteins 0.000 description 1
- 208000007475 Hemolytic Anemia Diseases 0.000 description 1
- 102000000543 Histamine receptors Human genes 0.000 description 1
- 108010002059 Histamine receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100004115 ICAM1 Human genes 0.000 description 1
- 101710002882 IKBKB Proteins 0.000 description 1
- 102100008724 IKBKB Human genes 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 229940100602 Interleukin-5 Drugs 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N Isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- 101700057035 KAT5 Proteins 0.000 description 1
- 102100002581 KAT5 Human genes 0.000 description 1
- 102100011311 KNG1 Human genes 0.000 description 1
- SFLSHLFXELFNJZ-MRVPVSSYSA-N L-Noradrenaline Natural products NC[C@@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-MRVPVSSYSA-N 0.000 description 1
- 101700021338 LEC Proteins 0.000 description 1
- 101700048515 LEC1 Proteins 0.000 description 1
- 101700046135 LEC2 Proteins 0.000 description 1
- 101700077545 LECC Proteins 0.000 description 1
- 101700028499 LECG Proteins 0.000 description 1
- 101700028593 LECH Proteins 0.000 description 1
- 101700063913 LECT Proteins 0.000 description 1
- 102100017376 LTA4H Human genes 0.000 description 1
- 102100002437 LTB4R Human genes 0.000 description 1
- 101710005170 LTB4R Proteins 0.000 description 1
- 102100012770 LTB4R2 Human genes 0.000 description 1
- 101710005169 LTB4R2 Proteins 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 102000003680 Leukotriene B4 receptors Human genes 0.000 description 1
- 108090000093 Leukotriene B4 receptors Proteins 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N Leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108091007472 MAP kinase family Proteins 0.000 description 1
- 102000038027 MAP kinase family Human genes 0.000 description 1
- 101710029927 MAPK10 Proteins 0.000 description 1
- 102100005527 MAPK10 Human genes 0.000 description 1
- 101710029924 MAPK8 Proteins 0.000 description 1
- 102100005531 MAPK8 Human genes 0.000 description 1
- 101710029922 MAPK9 Proteins 0.000 description 1
- 102100005528 MAPK9 Human genes 0.000 description 1
- 101710031876 MC1R Proteins 0.000 description 1
- 102100004664 MC1R Human genes 0.000 description 1
- 101710026550 MC2R Proteins 0.000 description 1
- 102100003920 MC2R Human genes 0.000 description 1
- 101700013240 MC3R Proteins 0.000 description 1
- 102100002883 MC3R Human genes 0.000 description 1
- 102100002884 MC4R Human genes 0.000 description 1
- 101700072329 MC4R Proteins 0.000 description 1
- 101700063493 MCP2 Proteins 0.000 description 1
- 210000001132 Macrophages, Alveolar Anatomy 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 229960002160 Maltose Drugs 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010088565 Melanocortin 5 receptor Proteins 0.000 description 1
- 102000019623 Melanocortin 5 receptor Human genes 0.000 description 1
- 108090000950 Melanocortin Receptors Proteins 0.000 description 1
- 102000004378 Melanocortin Receptors Human genes 0.000 description 1
- 210000000274 Microglia Anatomy 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 101700049309 NOS2 Proteins 0.000 description 1
- 102100002496 NOS2 Human genes 0.000 description 1
- 210000001989 Nasopharynx Anatomy 0.000 description 1
- 229960002748 Norepinephrine Drugs 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 101710034340 Os04g0173800 Proteins 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 102100010180 P2RX7 Human genes 0.000 description 1
- 101700064615 P2RX7 Proteins 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-O PAF Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(O)(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-O 0.000 description 1
- 101710029802 PLA2G4A Proteins 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- UXCDUFKZSUBXGM-UHFFFAOYSA-N Phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 229940068965 Polysorbates Drugs 0.000 description 1
- 241001506308 Potato virus T Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229960004063 Propylene glycol Drugs 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100003386 S100A12 Human genes 0.000 description 1
- 101710023382 S100A12 Proteins 0.000 description 1
- 108060007763 SLC6A4 Proteins 0.000 description 1
- 102100001823 SLC6A4 Human genes 0.000 description 1
- 206010040070 Septic shock Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Sodium cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N Sodium sulfide Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical class OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 229960000391 Sorbitan trioleate Drugs 0.000 description 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 101710040537 TNF Proteins 0.000 description 1
- 206010043554 Thrombocytopenia Diseases 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N Trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940045997 Vitamin A Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- CXNIUSPIQKWYAI-UHFFFAOYSA-N Xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- OWGUSBISUVLUJF-SDNWHVSQSA-N [(E)-(2-hexylcyclopentylidene)amino]thiourea Chemical compound CCCCCCC1CCC\C1=N/NC(N)=S OWGUSBISUVLUJF-SDNWHVSQSA-N 0.000 description 1
- PRXRUNOAOLTIEF-XDTJCZEISA-N [2-[(2R,3S,4R)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9-enoyl]oxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-XDTJCZEISA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N acetic acid;palladium Chemical compound [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000001476 alcoholic Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 201000004984 autoimmune cardiomyopathy Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000003008 brain-resident macrophage Anatomy 0.000 description 1
- LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 239000002713 epithelial sodium channel blocking agent Substances 0.000 description 1
- 101710024775 erkB Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- XVBZFXZNJAFCHL-UHFFFAOYSA-N ethyl 2-aminopyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC(N)=C1 XVBZFXZNJAFCHL-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 239000003396 histamine H4 receptor antagonist Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004093 hydrolase inhibitor Substances 0.000 description 1
- SXWRTZOXMUOJER-UHFFFAOYSA-N hydron;piperidin-4-one;chloride;hydrate Chemical compound O.Cl.O=C1CCNCC1 SXWRTZOXMUOJER-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 101700036391 lecA Proteins 0.000 description 1
- 108010072713 leukotriene A4 hydrolase Proteins 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- IXAQOQZEOGMIQS-SSQFXEBMSA-N lipoxin A4 Chemical compound CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O IXAQOQZEOGMIQS-SSQFXEBMSA-N 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 239000002697 lyase inhibitor Substances 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 101700019200 mrp4 Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229940096701 plain lipid modifying drugs HMG CoA reductase inhibitors Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002102 polyvinyl toluene Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000003590 rho kinase inhibitor Substances 0.000 description 1
- 230000001932 seasonal Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 108010014501 sphingosine 1-phosphate lyase (aldolase) Proteins 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical group 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003799 tocopherols Natural products 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Abstract
This invention relates to co-crystals and salts of CCR3 inhibitors of formula 1,
Description
FIELD OF THE INVENTION
This invention relates to co-crystals and salts of CCR3 inhibitors, pharmaceutical compositions containing one of those, and methods of using the same as agents for treatment and/or prévention of a wide variety of inflammatory, infectious, and immunoregulatory disorders and diseases, including asthma and allergie diseases, chronic obstructive pulmonary disease, infection by pathogenic microbes (including viruses), autoimmune pathologies such as the rheumatoid arthritis and atherosclerosis as well as age-related macular degeneration (AMD), diabetic retînopathy and diabetic macular edema.
BACKGROUND INFORMATION
Chemokines are chemotactic cytokines, of molecular weight 6-15 kDa, that are released by a wide variety of cells to attract and activate, among other cell types, macrophages, T and B lymphocytes, eosinophils, basophils and neutrophils (reviewed în Luster, New Eng. J Med., 338, 436-445 (1998); Rollins, Blood, 90, 909-928 (1997); Lloyd, Curr Opin Pharmacol., 3, 443-448 (2003); Murray, Current Drug Targets., 7, 579-588 (2006); Smit, Eur J Pharmacol., 533,277-88 (2006)
There are two major classes of chemokines, CXC and CC, depending on whether the first two cysteines in the amino acid sequence are separated by a single amino acid (CXC) or are adjacent (CC). The CXC chemokines, such as interleukin-8 (IL8), neutrophil-activating protein-2 (NAP2) and melanoma growth stimulatory actîvity protein (MGSA) are chemotactic primarily for neutrophils and T lymphocytes, whereas the CC chemokines, such as RANTES, ΜΙΡ-la, MIP-1, the monocyte chemotactic proteins (MCP-1, MCP-2, MCP-3, MCP-4, and MCP-5) and the eotaxins (-1 ,-2, and-3) are chemotactic for, among other cell types, macrophages, T lymphocytes, eosinophils, mast cells, dendritic cells, and basophils. Also in existence are the chemokines lymphotactin-1, lymphotactin-2
-116358 (both C chemokines), and fractalkine (a CXXXC chemokine) that do not fall into either of the major chemokine subfamilies.
The chemokines bind to spécifie cell-surface receptors belonging to the family of G-protein-coupled seventransmembrane-domain proteins (reviewed in Horuk, Trends Pharm. Sci., 15, 159-165 (1994); Murphy, Pharmacol Rev., 54 (2):227-229 (2002); Allen, Annu. Rev. Immunol., 25, 787-820 (2007)) which are termed chemokine receptors. On binding their cognate ligands, chemokine receptors transduce an intracellular signal through the associated trimeric G proteins, resulting in, among other responses, a rapid increase in intracellular calcium concentration, activation of G-proteins, changes in cell shape, increased expression of cellular adhesion molécules, degranulation, promotion of cell migration, survival and prolifération. There are at least eleven human chemokine receptors that bind or respond to CC chemokines with the following characteristic patterns: CCR-1 (orCKR-1orCC-CKR-1) [MlP-la, MCP-3, MCP-4, RANTES] (Ben-Barruch, et al., Cell, 72, 415-425 (1993), Luster, New Eng. J. Med., 338, 436445 (1998)); CCR-2A and CCR-2B (or CKR-2A7CKR-2BorCC-CKR-2A7CCCKR-2B) [MCP-1, MCP2, MCP-3, MCP-4, MCP-5] (Charo et al., Proc. Natl. Acad. Sci. USA, 91, 2752-2756 (1994), Luster, New Eng. J. Med., 338, 436-445 (1998)); CCR3 (orCKR-3orCC-CKR-3) [eotaxin-1, eotaxin-2, RANTES, MCP-3, MCP-4] (Combadiere, et al., J. Biol. Chem., 270, 16491-16494 (1995), Luster, New Eng. J. Med., 338, 436-445 (1998)); CCR-4 (orCKR-4 or'CC-CRR-^’) [TARC, MlP-la, RANTES, MCP-1] (Power et al., J. Biol. Chem., 270, 19495-19500 (1995), Luster, New Eng. J. Med., 338, 436-445 (1998)); CCR-5 (orCKR-5ORCCCKR-5) [MlPla, RANTES, MIP-lp] (Sanson, et al., Biochemistry, 35, 3362-3367 (1996)); CCR-6 (orCKR-6or CC-CKR-6) [LARC] (Baba et al., J. Biol. Chem., 272, 14893-14898 (1997)); CCR-7 (orCKR-7orCC-CKR-7) [ELC] (Yoshie et al., J. Leukoc. Biol.
62, 634-644 (1997)); CCR-8 (orCKR-8or,,CC-CKR-8) [1-309, TARC, MIP-1 p] (Napolitano et al., J. Immunol., 157, 2759-2763 (1996), Bernardini et al., Eur. J. Immunol., 28, 582-588 (1998)); CCR-10 (orCKR-10orCC-CKR-10) [MCP-1, MCP-3] (Bonini étal, DNA and Cell Biol., 16,1249-1256 (1997)) ; and CCR31 (or
-216358
CKR-11 or CC-CKR-11 ) [MCP-1, MCP-2, MCP-4]( Schweickart et al., J Biol Chem, 275 9550-9556 (2000)).
In addition to the mammalian chemokine receptors, the Decoy receptors CCXCKR, D6 and DARC/Duffy as well proteins expressed by mammalian cytomegaloviruses, herpes viruses and poxviruses, exhibit binding properties of chemokine receptors (reviewed by Wells and Schwartz, Curr. Opin. Biotech., 8, 741-748 (1997); Comerford, Bioessays., 29(3):237-47 (2007)). Human CC chemokines, such as RANTES and MCP-3, can cause rapid mobîlîzation of calcium via these virally encoded receptors. Receptor expression may be permissive for infection by allowing for the subversion of normal immune system surveillance and response to infection. Additionally, human chemokine receptors, such as CXCR-4, CCR2, CCR3, CCR5 and CCR8, can act as co receptors for the infection of mammalian cells by microbes as with, for example, the human immunodeficiency viruses (HIV).
Chemokine receptors hâve been implicated as being important mediators of inflammatory, infectious, and i mm uno regu lato ry dîsorders and diseases, including asthma and allergie diseases, as well as autoimmune pathologies such as rheumatoid arthritis, Grave’s disease, chronic obstructive pulmonary disease, and atherosclerosis. For example, the chemokine receptor CCR3 is expressed among others on eosinophils, basophils, TH2 cells, alveolar macrophages, mast cells, épithélial cells, microglia cells, astrocytes and fîbroblasts. CCR3 plays a pivotai raie in attracting eosinophils to sites of allergie inflammation and in subsequently activating these cells. The chemokine ligands for CCR3 induce a rapid increase in intraceliular calcium concentration, increased GTP exchange of G-proteins, increased ERK phosphorylation, enhanced receptor internalizatîon, eosinophil shape change, increased expression of cellular adhesion molécules, cellular degranulation, and the promotion of migration. Accordingly, agents that inhibit chemokine receptors would be useful in such dîsorders and diseases. In addition, agents that inhibit chemokine receptors would also be useful in infectious diseases
-316358 such as by blocking infection of CCR3 expressing cells by HIV or in preventing the manipulation of immune cellular responses by viruses such as cytomégaloviruses.
Therefore, CCR3 is an important target and antagonism of CCR3 is likely to be effective in the treatment of inflammatory, éosinophilie, immunoregulatory and infectious disorders and diseases (Wegmann, Am J Respir Cell Mol Biol., 36(1 ):61-67 (2007); Fryer J Clin Invest., 116(1):228-236 (2006); De Lucca, Curr Opin Drug Discov Devel., 9(4):516-524 (2006)
So, the problem underlying the présent invention was the provision of CCR3 antagonists, preferred with reduced side effects which are not only potent CCR3inhibitors, but also are useful for manufacturing a médicament for the prévention and/or treatment of diseases wherein the activity of a CCR3-receptor is involved.
It has been found surprisingly that the substituted pîperidines of formula 1 are highly suitable as CCR3 antagonists, having less side effects, e.g. inhibition of norepinephrine (NET), dopamine (DAT) or serotonin reuptake transportera (5HTT) as described by Watson PS, Bioorg Med Chem Lett., 16(21):5695-5699 (2006), or inhibition of 5HT2A, 5HT2C or Dopamine D2 receptors as described by De Lucca, J Med Chem., 48(6):2194-2211(2005), or inhibition of the hERG channel as described by De Lucca, Curr Opin Drug Discov Devel., 9(4):516-524 (2006), or inhibition of the alphalB adrenergic receptor.
Nevertheless such compounds are bases and thus could be problematic for the manufacturing of a médicament since their physical behaviour can cause problems fînding a suitable pharmaceutical form. This could be structural problème like stability, light sensitiveness or déliquescence, but also physical problem e.g. if a compound is not soluble or not suitable for common manufacturing processes like milling.
Now, it has been surprisingly found that the claimed co-crystals or salts of the compounds of formula 1 are fulfilling enough criteria for a pharmaceutical
-416358 development to manufacture a médicament as above described e.g. a sufficient stability, a controllable déliquescence, a solubility high enough to be useful as a médicament, a solid state useful for standard manufacturing processes or a sufficiently defined crystal form.
DESCRIPTION OF THE INVENTION
Subject matter of the instant invention is co-crystals of compounds of formula 1
(HX)j wherein
R1 is C-i-e-alkyl, Ci-e-haloalkyl, O-C-.6-haloalkyl, halogène;
m is 1, 2 or 3; preferably 1 or 2;
R2a and R2b are each independently selected from H, Ci-e-alkyl, Ci^-alkenyl, Ci-e-alkynyl, C3.6-cycloalkyl, COO-Ci.6-alkyl, O-Ci_6-alkyl, CONR2b1R2b2, halogène;
R2b 1 is H, Ci-6-alkyl, C0.4-alkyl-C3.6-cycloalkyl, Ci.6-haloalkyl;
R2b2 is H, Cve-alkyl;
or R2b 1 and R2b 2 are together a C3.6-alkylene group forming with the nitrogen atom a heterocyclic ring, wherein optionally one carbon atom or the ring îs replaced by an oxygen atom
-516358
R3 is H, Ci-6-alkyl;
X is an anion selected from the group consisting of chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, fumarate, tartrate, dibenzoyltartrate, oxalate, succinate, benzoate and p-toluenesulphonate; preferably chloride or dibenzoyltartrate j is 0, 0.5, 1, 1.5 or 2; preferably 1 or 2;
with a co-crystal former selected from the group consisting of orotic acid, hippuric acid, L-pyroglutamic acid, D-pyroglutamic acid, nicotinic acid, L-(+)-ascorbîc acid, saccharin, piperazine, 3-hydroxy-2-naphtoic acid, mucic (galactaric) acid, pamoic (embonic) acid, stearîc acid, cholic acid, deoxycholic acid, nicotinamide, isonicotinamide, succinamide, uracil, L-lysine, L-proline, D-valine, L-arginine, glycine, preferably ascorbic acid, mucic acid, pamoic acid, succinamide, nicotinic acid, nicotinamide, isonicotinamide, l-lysine, l-proline,
Those co-crystals are useful for manufacturing a médicament for the prévention and/or treatment of diseases wherein the activity of a CCR3-receptor is involved.
Another aspect of the invention are co-crystals of compounds of formula 1, wherein
R2a is H, C-i-e-alkyl, Ci-e-alkenyl, Οτ-e-alkynyl, C^cycloalkyl, O-Ci.6-alkyl, CONR2a1R2a2;
R2a/I is H, Ci.6-alkyl, C1f:-haloalkyl;
R2a2 is H, Ci-6-alkyl;
R2b is H, Ci-e-alkyl, Ci_6-alkenyl, Ci_6-alkynyl, C3-6-cycloalkyl, COO-Ci-e-alkyl, OCi-e-alkyl, CONR2br1R2b2, halogène;
-616358
R2b 1 is H, Ci.6-alkyl, Co-4'alkyl-C3-6-cycloalkyl, Ci.6-haloalkyl;
R2b'2 îs H, Ci-e-alkyl;
or R2b 1 and R2b 2 are together a C3.6-alkylene group forming with the nitrogen atom a heterocyclic ring, wherein optionally one carbon atom or the ring is replaced by an oxygen atom and the remaining residues are defined as above.
Another aspect of the invention are co-crystals of compounds of formula 1, wherein
R2a is H, Ci.6-alkyl, Cve-alkynyl, C3.6-cycloalkyl, O-Ci.6-alkyl, CONR2a 1R2a2;
R2a 1 is Cve-alkyl;
R2a·2 is H;
R2b is H, Ci.6-alky[, O-Ci.6-alkyl, CONR2b 1R2b2;
R2bJ is Ci_6-alkyl, C0-4-alkyl-C3-6-cycloalkyl, Ci_6-haloalkyl;
R2b·2 is H, C^-alkyl;
or R2b1 and R2b 2 are together a C3.6-alkylene group forming with the nitrogen atom a heterocyclic ring, wherein optionally one carbon atom or the ring is replaced by an oxygen atom and the remaining residues are defined as above.
Anotheraspect ofthe invention are co-crystals of compounds of formula 1, wherein
R2a is H, Ci-4-alkyl, C^-alkynyl, C3-6-cycloalkyl, O-Ci-4-alkyl, CONR2a 1R2a 2; w/
-716358
R2a'1 is Ci.4-alkyl;
R2a 2 is H;
s R2b is H, CM-alkyl, O-Ci_4-alkyl, CONR2b 1R2b2;
R2b 1 is C-M-alkyl, Co^-alkyl-Cs 6-cycloalkyl, Ci-4-haloalkyl;
R2b 2 is H, Ci.4-alkyl;
io or R2b 1 and R2b 2 are together a C3-e-alkylene group forming with the nitrogen atom a heterocyclic ring, wherein optionally one carbon atom or the ring is replaced by an oxygen atom and the remaining residues are defined as above.
Another aspect of the invention are co-crystals of compounds of formula 1, wherein
R2a is H, C-M-alkyl,
2û R2b is H, CONR2b1R2b2;
R2b 1 is C-i_4-alkyl, C0-4-alkyl-C3.6-cycloalkyl, C-ι .-.-haloalkyl; R2b2 is H, Ci.4-alkyl;
or R2b 1 and R2b 2 are together a C3-6-alkylene group forming with the nitrogen atom a heterocyclic ring, wherein optionally one carbon atom or the ring is replaced by an oxygen atom and the remaining residues are defined as above.
Another aspect of the invention are co-crystals of compounds of formula 1, wherein
-816358
R1 is C-i-e-alkyl, Ci.6-haloalkyl, O-Ci-e-haloalkyl, halogène;
m is 1 or 2;
R2a is H, Ci_4-alkyl;
R2b is H, CONR2bJR2b2;
R2b 1 is Ci.4-alkyl, C0.4-alkyl-C3.6-cycloalkyl, Ch ^-haloalkyl;
R2b·2 is H, C-M-alkyl;
or R2b 1 and R2b 2 are together a C3.6-alkylene group forming with the nitrogen atom a heterocyclic ring, wherein optionally one carbon atom or the ring is replaced by an oxygen atom
R3 is H, Ci-6-alkyl;
X is an anion selected from the group consisting of chloride or dibenzoyltartrate j is 1 or 2.
Another aspect of the invention are co-crystals of compounds of formula 1, wherein
R2a is H, Ci-4-alkyl; preferably Methyl, Ethly, Propyl;
R2b is H, CONR2b 1R2b2;
R2b 1 îs C-M-alkyl; preferably Methyl, Ethly, Propyl;
R2b·2 is Ci-4-alkyl; preferably Methyl, Ethly, Propyl;
and the remaining residues are defined as above
-916358
Another aspect of the invention are co-crystals of compounds of formula 1, wherein
R2a is H, C-M-alkyl; preferably Methyl, Ethly, Propyl;
R2b isH, CONR2b1R2b2;
R2b1 is Co-4-alkyl-C3-6-cycloalkyl;
R2b·2 is H, Ci.4-alkyl; preferably H, Methyl, Ethly, Propyl;
and the remaîning residues are defined as above.
Another aspect of the invention are co-crystals of compounds of formula 1, wherein
R2a is H, Ci-4-alkyl; preferably Methyl, Ethly, Propyl;
R2b is H, CONR2b1R2b2;
R2b1 is Ci-4-haloalkyl;
R2b-2 is H, Ci-4-alky; preferably H, Methyl, Ethly, Propyl;
and the remaîning residues are defined as above.
Another aspect of the invention are co-crystals of compounds of formula 1, wherein
R2b 1 and R2b2 are together a C3-6-aikylene group forming with the nitrogen atom a heterocyclic ring, wherein optionally one carbon atom or the ring is replaced by an oxygen atom and the remaîning residues are defined as above.
-1016358
Another aspect of the invention are co-crystals of compounds of formula 1, wherein R1, m, R2a, R2b, R3, X and j are defined as above and the co-crystal former is selected from the group consisting of ascorbic acid, mucic acid, pamoic acid, succinamide, nicotinic acid, nicotinamide, isonicotinamide, l-lysine, l-proline, or hydrates or hydrochlorides ofthe same.
Another aspect of the invention are co-crystals of compounds of formula 1a, wherein R2a, R2b, R3, X and j are defined as above
Cl
Another aspect of the invention are co-crystals of compounds of formula 1a, wherein
R2a is H, C-i-4-alkyl; preferably Methyl, Ethly, Propyl;
R2b is H, CONR2b1R2b 2;
R2b 1 is Ci.4-alkyl; preferably Methyl, Ethly, Propyl;
R2b2 is Ci-4-alkyl; preferably Methyl, Ethly, Propyl;
and the remaining residues are defined as above.
Another aspect of the invention are co-crystals of compounds of formula 1a, wherein
is H, Ci-4-alkyl; preferably Methyl, Ethly, Propyl;
is H, CONR2b1R2b2;
-1116358
R2b1 is Co-4-alkyl-C3.6-cycloalkyl;
R2b·2 is H, CV4-alkyl; preferably H, Methyl, Ethly, Propyl;
and the remaining residues are defîned as above.
Another aspect of the invention are co-crystals of compounds of formula 1a, wherein
R2a is H, C-M-alkyl; preferably Methyl, Ethly, Propyl;
R2b is H, CONR2b 1R2b2;
R2b 1 is C-M-haloalkyl;
R2b2 is H, Ci-4-alky; preferably H, Methyl, Ethly, Propyl;
and the remaining residues are defîned as above.
Another aspect of the invention are co-crystals of compounds of formula 1 a, wherein
R2b1 and R2b 2 are together a C3-6-alkylene group forming with the nitrogen atom a heterocyclic ring, wherein optionally one carbon atom or the ring is replaced by an oxygen atom and the remaining residues are defîned as above.
The free bases of compounds of formula 1 (j = 0) are often amorphous and are used for a process of manufacturing co-crystal, nevertheless salts of compounds of formula 1 are preferred for a process of manufacturing co-crystal. Thus, another aspect of the invention are salts of compounds of formula 1 wherein R1, m, R2a, R2b, R3 are defîned as for the co-crystals above and —
-1216358
X is an anion selected from the group consisting of chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, fuma rate, tartrate, dibenzoyltartrate, oxalate, succinate, benzoate and p-toluenesulphonate; preferably chloride, or dibenzoyltartrate j is 0, 0.5, 1, 1.5 or 2; preferably 1 or 2.
Another aspect of the invention are salts of compounds of formula 1, wherein R1, m, R2a, R2b, R3 are defined as for the co-crystals above and
X is an anion selected from the group consisting of chloride or dibenzoyltartrate j is 1 or 2.
Another aspect of the invention are salts of compounds of formula 1, wherein R1, m, R2a, R2b, R3 are defined as for the salts above and X is chloride and j is 2.
Another aspect of the invention are salts of compounds of formula 1, wherein R1, m, R2a, R2b, R3 are defined as for the salts above and X is dibenzoyltartrate and j is
1.
Another aspect of the invention are salts of compounds of formula 1a, wherein R2a, R2b, R3, X and j are defined as above ,2a
Cl (HX)j
1a.
Another aspect of the invention are salts of compounds of formula 1a, wherein
-1316358
îs H, C-M-alkyl; preferably Methyl, Ethly, Propyl; is H, CONR2b 1R2b2;
is C-M-alkyl; preferably Methyl, Ethly, Propyl;
R2b2 is C-M-alkyl; preferably Methyl, Ethly, Propyl;
and the remaining residues are defined as above.
w Another aspect of the invention are salts of compounds of formula 1a, wherein
R2a is H, CM-alkyl; preferably Methyl, Ethly, Propyl;
R2b is H, CONR2b1R2b2;
R2b 1 is C0-4-alkyl-C3-6-cycloalkyl;
R2b2 is H, Ci-4-alkyl; preferably H, Methyl, Ethly, Propyl;
and the remaining residues are defined as above.
Another aspect of the invention are salts of compounds of formula 1a, wherein
R2a is H, Ci-4-alkyl; preferably Methyl, Ethly, Propyl;
R2b is H, CONR2bJR2b·2;
R2b 1 îs Ci_4-haloalkyl;
R2b 2 is H, C-M-alky; preferably H, Methyl, Ethly, Propyl;
and the remaining residues are defined as above.
3o Another aspect of the invention are salts of compounds of formula 1 a, wherein
-1416358
R2b 1 and R2b 2 are together a C3.6-alkylene group forming with the nitrogen atom a heterocyclic ring, wherein optionally one carbon atom or the ring is replaced by an oxygen atom and the remaining residues are defined as above.
Another aspect of the invention are salts of compounds of formula 1a, wherein R1, m, R2a, R2b, R3 are defined as for the salts above and X is chloride and j is 2.
Anotheraspect ofthe invention are salts of compounds offormula 1a, wherein R1, m, R2a, R2b, R3 are defined as for the salts above and X is dibenzoyltartrate and j is
1. Another aspect of the invention are salts of compounds of formula 1a, wherein R1, m, R2a, R2b, R3 are defined as for the salts above and X is ( S )-(S )-(+)-2,3dibenzoyl-tartrate and j is 1.
The above mentioned salts are also useful for manufacturing a médicament for the prévention and/or treatment of diseases wherein the activîty of a CCR3-receptor is involved.
Another aspect of the invention are co-crystals or salts of the compounds of the examples 1 to 36 from the -Synthesis of Examples- section below with an acid (HX)j wherein X is an anion selected from the group consisting of chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, fumarate, tartrate, dibenzoyltartrate, oxalate, succînate, benzoate and p-toluenesulphonate; preferably chloride or dibenzoyltartrate and j îs 0, 0.5, 1, 1.5 or 2; preferably 1 or 2; and in case of the co-crystals with a co-crystal former selected from the group consisting of orotic acid, hippuric acid, L-pyroglutamic acid, D-pyroglutamic acid, nicotinic acid, L-(+)ascorbic acid, saccharin, piperazine, 3-hydroxy-2-naphtoic acid, mucic (galactaric) acid, pamoic (embonic) acid, stearic acid, cholic acid, deoxycholic acid, nicotinamide, isonicotinamide, succinamide, uracil, L-lysine, L-proline, D-valine, L-s^y—
-1516358 arginine, glycine, preferably ascorbic acid, mucic acid, pamoic acid, succinamide, nicotinic acid, nicotinamide, isonicotinamide, l-lysine, l-proline,
Another aspect of the invention are co-crystals or salts of the compounds of the examples 1 to 36 from the -Synthesis of Examples- section below with an acid (HX)j wherein X is an anion selected from the group consisting of chloride or dîbenzoyltartrate and j is 1 or 2; and in case of the co-crystals with a co-crystal former selected from the group consisting of ascorbic acid, mucic acid, pamoic acid, succinamide, nicotinic acid, nicotinamide, isonicotinamide, l-lysine, l-proline,
Especially the dihydrochloride sait and the (S)-(S)-(+)-2,3-dibenzoyl-tartrate salts □f a compound of formula 1,1a or the examples 1 to 36 from the -Synthesis of Examples- section below are preferred examples of the invention which are useful for the préparation / manufacture of the above described co-crystals and/or for manufacturing a médicament for the prévention and/or treatment of diseases wherein the activity of a CCR3-receptor is involved.
In the context of this invention if dîbenzoyltartrate is mentioned the preferred enantiomere of dîbenzoyltartrate is always (S)-(S)-(+)-2,3-dibenzoyl-tartrate.
Another aspect of the invention are novel intermediates for manufacturing the compounds of formula 1. Those intermediates are obtainable from commercially available educts as described in the experimental section below.
112
113
114
-1616358
The apostrophe ' symbolizes in this context the différence between the name giving structure shwon in the experimental section and the novel intermediate. The différence is that R1 is restricted to Cl and Me and m is 1.
USED TERMS AND DEFINITIONS
Terms not specifically defined herein should be given the meanings that would be given to them by one of skîll in the art in light of the disclosure and the context. As used în the spécification, however, unless specified to the contrary, the following terms hâve the meaning indicated and the following conventions are adhered to. In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, Cve-alkyl means an alkyl group or radical having 1 to 6 carbon atoms. In general, for groups comprising two or more subgroups, the first named subgroup is the radical attachment point, for example, the substituent Ci 3-alkyl-aryl means an aryl group which is bound to a Ci-3-alkyl-group, the latter of which is bound to the core or to the group to which the substituent is attached.
In case a compound of the présent invention is depicted in form of a chemical name and as a formula in case of any discrepancy the formula shall prevail. An asterisk is may be used in sub-formulas to indicate the bond which is connected to the core molécule as defined. —
-1716358
Unless specifically indicated, throughout the spécification and the appended claims, a given chemical formula or name shall encompass tautomers and ail stéréo, optical and geometrical isomers (e.g. enantiomers, diastereomers, E/Z isomers etc...) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts thereof and solvatés thereof such as for instance hydrates including solvatés of the free compounds or solvatés of a sait of the compound.
The term halogène generally dénotés fluorine, chlorine, bromine and iodine.
The term Ci.n-alkyl, wherein n is an integer from 2 to n, either alone or in combination with another radical dénotés an acyclic, saturated, branched or linear hydrocarbon radical with 1 to n C atoms. For example the term C-i.5-alkyl embraces the radicals H3C-, H3C-CH2-, Η3Ο-ΟΗ2-ΟΗ2-, H3C-CH(CH3)-, H3C-CH2-CH2-CH2-, H3C-CH2-CH(CH3)-, H3C-CH(CH3)-CH2-, H3C-C(CH3)2-, H3C-CH2-CH2-CH2-CH2-, H3C-CH2-CH2-CH(CH3)-, H3C-CH2-CH(CH3)-CH2-, H3C-CH(CH3)-CH2-CH2-, H3C-CH2-C(CH3)2-. H3C-C(CH3)2-CH2-, H3C-CH(CH3)-CH(CH3)- and H3C-CH2-CH(CH2CH3)-.
The term Ch.n-haloalkyl”, wherein n is an integer from 2 to n, either alone or in combination with another radical dénotés an acyclic, saturated, branched or linear hydrocarbon radical with 1 to n C atoms wherein one or more hydrogen atoms are replaced by a halogène atom selected from among fluorine, chlorine or bromine, preferably fluorine and chlorine, particularly preferably fluorine. Examples include: CH2F, chf2, cf3.
The term Cpn-alkylene wherein n is an integer 2 to n, either alone or in combination with another radical, dénotés an acyclic, straight or branched chain divalent alkyl radical containing from 1 to n carbon atoms. For example the term
-1816358
Ci-4-alkylene includes -CH2-, -CH2-CH2-, -CH(CH3)-, -CH2-CH2-CH2-, -C(CH3)2-,
-CH(CH2CH3)-, -CH(CH3)-CH2-, -CH2-CH(CH3)-, -CH2-CH2-CH2-CH2-,
-CH2-CH?-CH(CH3)-, -CH(CH3)-CH2-CH2-, -CH2-CH(CH3)-CH2-, -CH2-C(CH3)2-,
-C(CH3)2-CH2-, -CH(CH3)-CH(CH3)-, -CH2-CH(CH2CH3)-f -CH(CH2CH3)-CH2-,
-CH(CH2CH2CH3)-, -CH(CH(CH3))2- and -C(CH3)(CH2CH3)-.
The term C?.n-alkenyl”. is used for a group as defined in the définition for Ci-n-alkyl with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a double bond.
The term C2 r.-alkynyl, is used for a group as defined in the définition for Ci-n-alkyl with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a triple bond.
The term C3.n-cycloalkyrt wherein n is an integer from 4 to n, either alone or in combination with another radical dénotés a cyclic, saturated, unbranched hydrocarbon radical with 3 to n C atoms. For example the term C3-7-cycîoalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
PREPARATION
PREPARATION OF COMPOUNDS OF FORMULA 1
The examples of the présent invention, represented by general structure 1, can be synthesized via methods 1 to 6 as outlined below where m, R1, R2a and R2b are defined as above and Xs is chloro or bromo and Y is methyl or ethyl. These methods are directly or indirectîy dépendent on Intermediate A which is synthesized according to scheme I. If not mentioned otherwîse the starting materials are commercially avaîlable.
-1916358 scheme
Method 1
Intermediate A
-2016358
Method 2
Stepl
Intermediate A ------Step2
I7 -----I8
Step3
Examples
Method 3A | |||
Intermediate A | Stepl | Examples | |
Method 3B | |||
Intermediate A | Step1 | Step 2 111 -----!—» | Examples |
Examples
Method 5
Stepl
-------Step2 ________
Step3 ______». Examples
Method 6 S'
-2116358
Synthesis of Intermediate A (Exemplified with R1 is 4-chloro-3-methyl)
Step 1: 4-Chloro-3-methyl benzylbromide (20 g) [synthesîzed according to literature: J.L. Kelley, JA. Linn, J.W.T. Selway, J. Med. Chem. 1989, 32(8), 17571763], 4-Piperîdone (22 g), K2CO3 (26 g) in acetonitrile (300 ml) is heated at 50°C for 14h. The suspension is filtered and the filtrate concentrated in vacuum. The residue is purified by flash chromatography (cyclohexane/ EtOAc 1:1) to yield intermediate 11 (17.4 g).
Step 2: Intermediate 11 (10 g) and D-H-Glu(OlBu)-OMe (10.8 g) are dissolved in DMF (200 ml) and HOAc (5 ml). Then molecular sieves (1.0 g, 4A, powder) are added and the suspension stirred overnight. Sodium triacetoxyborohydride (37.5
g) is added and the suspension stirred until complété conversion of the intermediate formed imine is observed. A basic pH is achieved by slow addition of aqueous NaHCO3 solution before additional water and dichloromethane (500 mL) is added. The organic phase is separated and the water phase extracted with dichloromethane (500 ml). The organic phase is washed with brine, dried and concentrated in vacuum to yield intermediate I2 (19.5 g).
Step 3: Intermediate I2 (19.5 g, 74% purity) is dissolved in dichloromethane (40 ml) and trifluoroacetic acid (20 ml). The solution is stirred at 25°C for 14 h before additional TFA (40 ml) is added and the solution continued stirring for further 7 h. The reaction mixture is then concentrated in vacuum, dissolved in toluene and concentrated again to provide intermediate I3 (29.5 g), -2216358
Step 4: Intermediate I3 (29 g, purity 55%) is dissolved in a mixture of dichloromethane (100 ml) and DIPEA (22 ml). TBTU (15 g) is added and the solution îs stirred for 30 min. Then dichloromethane (150 ml), water (100 ml) and saturated NaHCO3 solution (100 ml) is added, the organic phase separated and the water phase extracted once with dichloromethane (100 ml). The organic phase is dried and concentrated to provide an oil which is then fractionated via reversed phase HPLC. The desired fractions are concentrated in vacuum, then a basic pH is adjusted with addition of NaHCO3 solution and the product extracted with dichloromethane to provide intermediate I4 (8.1 g).
Step 5: Intermediate I4 (7g) is dissolved in dioxane (50 ml). LiOH (2.5M aqueous solution, 23 ml) and water (20 ml) are added and stirred at room température overnight. The solution is acidified with aqueous 4N HCl and then concentrated in vacuum. The residue is dissolved in water, acetonitrile and a small amount of dioxane and lyophilised to provide of intermediate A (10.4 g, 71% purity).
Alternative Route to Intermediate A (Exemplified with R1 is 4-chloro-3-methyl)
Step 1: 4-Chloro-3-methyl benzylchloride (85.7 g), 4-piperidone-hydratehydrochloride (80.5 g) and K2CO3 (141.8 g) are heated at reflux for 3.5h in a 1:1 mixture of dioxane/water (600 ml). The suspension is cooled to room température and water (200 ml) is added. Afterwards, the mixture is extracted with toluene (2 x 400 ml). The combined organic phases are washed with brine (2 x 400 ml), dried over Na2SC>4 and filtered. After évaporation to dryness, intermediate 11 [110.8 g, Rf = 0.27 (TLC, silica, ΡΕ/EtOAc = 7:3)] is obtained.
Step 2+3+4: D-H-Glu(OMe)-OMe*HCI (11.4 g) and intermediate 11 (11.4g) are dissolved in DMF (35 ml) and stirred at room température for 2h. Then, a solution of NaBH(OAc)3 (36.8 g) in DMF (40 ml) is added at below 15°C. The mixture is warmed to room température and stirred for 30 minutes. Now a compound of formula I3'-Me Ύ
-2316358
MeOOC^^^ACOOMe
can be isolated or AcOH (0.3 ml) is added without isolation of a intermidiate product and the mixture is heated to 105°C for 1.5 h. The mixture is cooled to room température and cold water (188 ml) is added. The pH is adjusted to pH = 8 by addition of NaOH (50% solution in water). Finally, the mixture is extracted with fert-butylmethylether (3 x 75 ml), the combined organic phases are washed with brine (1 x 50 ml), dried over Na2SO4 and filtered. After évaporation to dryness, intermediate I4 [15.9 g, ee = 98.3%, Rf = 0.30 (TLC, silica, toluene/EtOH = 85:15)] is obtained.
Step 5: Intermediate I4 (150.3 g) is dissolved in MeOH (526 ml), 4N NaOH (145.7 ml) is added and the mixture is heated to reflux for 2h. Afterwards, MeOH is distilled off and water (500 ml) is added. The mixture is extracted with tertbutylmethylether (2 x 300 ml). The aqueous phase is diluted with water (402 ml) and the pH is adjusted to pH=6.5 by addition of 4N HCl. The suspension is cooled to 5°C and stirred for an additional 2h. Finally, the mixture is filtered, the residue washed with water and dried to yield intermediate A [107.8 g, ee > 99.0%, m.p.: 260 ± 3°C, Rf = 0.2 (TLC, silica, toluene/EtOH = 9:1]).
SYNTHESIS OF EXAMPLES
Synthesis of Examples via Method 1 (Exemplified with R1 is 4-chloro-3-methyl;
R2a is ethyl; R2b is Ν,Ν-dimethylcarboxamido; Xs is bromo; Y is methyl). '
-2416358
Step 1: Intermediate A, as its Ν,Ν-diisopropylethylamine sait (500 mg), is suspended in dry DMF (7 ml) under inert atmosphère and TBTU (836 mg) is added, followed by Ν,Ν-diisopropylethylamine (0.53 ml). After stirring for 1 h at room température, hexamethyldisilazane (0.44 ml) is added and the mixture îs stirred for 6 h. Further portions of TBTU (334 mg) and hexamethyldisilazane (0.22 ml) are added and the reaction is stirred for a further 18 h. The solvent is evaporated under reduced pressure and residue partitioned between saturated aqueous solution of NaHCO3 and EtOAc. The layers are separated and the aqueous phase extracted with EtOAc. The combined organic extracts are washed with brine, dried under Na2SO4, filtered and the solvent is evaporated under reduced pressure. The crude is purified by flash chromatography (20 g Isolute® silica gel cartridge; eluent: dichloromethane/MeOH/NH4OH 95/5/0.5) affording 15 (295 mg). UPLC (Rt) = 1.24 min (method M)
Step 2: To a stirred solution of citrazinic acid (15 g) is added phosphorous oxybromide (45 g) and the mixture heated to140°C. After 14 h the mixture is cooled to 0°C and MeOH (100 ml) added carefully under vigorous stirring. The mixture is then poured into a cooled (0°C) aqueous sodium carbonate solution (1 M, 500ml), and chloroform (500 ml) is added. The bîphasic mixture is filtered and the organic layer separated. After filtering through charcoal, the solution is concentrated in vacuum. The residue is purified by MPLC (dichloromethane:MeOH 100:3 to 100:6) to yield methyl 2,6-dibromoisonicotinate (13.7 g). HPLC (Rt) = 1.62 (method D). To a stirred solution of I5 (2.6 g) in dioxane (30 ml) under argon is added methyl 2,6-dÎbromoisonicotinate (2.2g), palladium acetate (167mg), Xanthphos (432mg) and Cs2CO3 (5.6g) and the mixture refluxed for 1 h. The mixture is allowed to cool to room température and then added to water and extracted with EtOAc. The organic extracts are washed with brine, dried under Na2SO4, filtered and the solvent evaporated under reduced pressure. The crude product is purified by HPLC (Method E) affording 16 (0.6 g).
Step 3: To a stirred solution of I5 (500mg) in dioxane (10 ml) under Argon is added 1,T-bis(diphenylphosphino)ferrocenedichloropalladium(ll) (65 mg)and γ~'
-2516358 diethylzinc (1M in hexane, 1.1 ml). The mixture is refluxed for 2 h then allowed to cool to rt. It is then quenched with NH4CI(aq) and extracted with EtOAc. The organic extracts are washed with brine, dried under Na2SO4, filtered, and the solvent evaporated under reduced pressure affording I7.
Step 4: (The procedure for Step 5 in the synthesis of Intermediate A is utilised with a reaction température of 50°C). I8 is afforded (137 mg). HPLC (Rt) = 1.32 min (method D).
Step 5: To a stirred solution of 18 (SOOmg) in DMF (10 ml) is added TBTU (772 mg), DIPEA (0.7 ml) and dimethylamine (0.36 g). After 2 h the reaction is quenched with water and extracted with EtOAc. The organic extracts are washed with brine, dried under Na2SO4, filtered, and the solvent evaporated under reduced pressure affording example 25 (410mg). HPLC (Rt) = 1.32 min (method D).
Synthesis of Examples via Method 2 (Exemplifïed with R1 is 4-chloro-3-methyl; R23 is hydrogen; R2b is N-methylcarboxamido; Y is ethyl).
Step 1: To a stirred solution of Intermediate A (0.48 g) in dichloromethane (5 ml) is added oxalylchloride (2M in dichloromethane, 2.5 ml). After 2 h, the réaction mixture is concentrated under reduced pressure. A suspension of 2-aminoisonîcotinic ethyl ester (0.51 g) in pyridine (1 ml) and dioxane (2 ml) is added to the reaction mixture and this stirred for 10 min. The mixture was concentrated under reduced pressure to afford I7 (0.3 g). HPLC (Rt) = 1.37 min (method D).
Step 2: (The procedure for Step 5 in the synthesis of Intermediate A was utilised). I8 was afforded (55 mg). HPLC (Rt) = 1.23 min (method D).
Step 3: To a stirred solution of I8 (55 mg) at room température is added HATU (60 mg), DMF (1 ml) and DIPEA (0.07 ml). After 5 min methylamine (2M in THF, 0.2 ml) is added. After another 5 min, water is added and the mixture acîdified with
-2616358
TFA, The crude product is purified by HPLC affording example 8 (50 mg). HPLC (Rt) = 1.22 min (method D).
2-Amino-6-methylisonicotinic acid methyl ester also relevant for Step 1 is prepared as follows:
Step a: 2-chloro-6-methylisonicotmic acid (9 g), of aq ammonia (44 ml), of Cu(ll)SO4 (0.9 g) and of sodium sulphide (0.32 g) are added to an autoclave and heated to 155°C overnight. The crude product is suspended in water to yield 2amino-6-methylisonicotinic acid (3.6 g). HPLC: Rt = 0.37 min (method D)
Step b: To 50 ml of MeOH is added drop wise acetyl chloride (3 ml) at room température. After 15 min, 2-amino-6-methylisonicotinic acid (2.3 g) is added and the mixture is stirred overnight at 50°C. After concentrating the solution, the resulting residue is suspended in acetone and then filtered and dried at 50°C in vacuum, to yield 2-amino-6-methylisonÎcotinic acid methyl ester (4.1g). HPLC: Rt = 0.91 min (method D)
Synthesis of Examples via Method 3A (Exemplified with R1 is 4-chloro-3-methyl; R2a is methyl; R2b is N,N-dimethylcarboxamido).
Step 1: Intermediate A (8.30 g), 2-amino-6,/V,A/-trimethylisonicotinamide (4.24 g) and NEt3 (43 ml) are mixed in THFabs. (66 ml) and heated to 55°C. T3P (50% solution in EtOAc, 56 ml) is added and the reaction mixture is stirred 1h. After cooling to room température EtOAc (66 ml) and water (50 ml) is added. The phases are separated and the aqueous phase is extracted with EtOAc (1 x 50 ml). The combined organic phases are washed with brine and dried over Na2SO4. After filtration, the solvent is removed in vacuum to yield example 11 [9.78g, R{ = 0.55 (TLC, silica, toluene/EtOH = 3:2)].
Synthesis of dîbenzoyltartrate sait W'”
-2716358
Example 11 (200 mg), EtOH (0.8 ml) and water (0.4 ml) are mixed and heated to
70°C. A solution of (S)-(S)-(+)-2,3-dibenzoyl-tartaric acid (175 mg) in EtOH (0.6 ml) and water (0.6 ml) is added. After cooling to room température the precipîtate is fîltered, washed with EtOH/H2O (7:3) and dried to afford the (S)-(S)-(+)-2,3dibenzoyl-tartrate of example 11 (200 mg).
Synthesis of Examples via Method 3B (Exemplified with R1 is 4-chloro-3-methyl; R2a is methyl; R2b is N,N-dimethylcarboxamido).
Step 1: Intermediate A (73.3g) and NEt3 (117 ml) are mixed in dry THF (440 ml) and T3P (50% solution in EtOAc, 246 ml) is added. The mixture is warmed to 50°C for 30 minutes and 2-Amino-6-methylisonicotinic acid methyl ester (34.7 g) is added. After stirring over night, the reaction mixture is cooled to room température and water (440 ml) and 4N NaOH (52 ml) are added. The phases are separated and the aqueous phase is extracted with iPrOAc (2 x 220 ml). The combined organic phases are washed with water (2 x 220 ml), dried over Na2SO4, fîltered and evaporated to dryness to a yield intermediate 111. [99.1 g, m.p.: 155 ± 3°C, Rf - 0.29 (TLC, silica, toluene/EtOH = 85:15)].
Cl
111
Step 2: Intermediate 111 (138.6 g) is suspended in iPrOH (415 ml) and NaOH (50% solution in water, 14.5 ml) is added. The mixture is heated to 55°C for 1h. Afterwards, the solvent is removed in vacuum and the residue is co-distilled with iPrOH (2 x 200 ml) and MeTHF (1 x 500 ml). Then, dry MeTHF (701 ml), Me2NH vZ
-2816358 (2M solution in THF, 208 ml) and NEt3 (117 ml) are added and the mixture is warmed to 50°C. T3P (50% solution in EtOAc, 327.4 ml) is added and the reaction mixture is stirred for an additional 1.5 h at 50°C. After cooling to room température water (818 ml) is added. The phases are separated and the aqueous phase is extracted with ÎPrOAc (2 x 281 ml). The combined organic phases are washed with water (2 x 281 ml), dried over Na2SO4, filtered and evaporated to dryness. The residue (crude example 11 ) is dissolved in acetone (1.46 L) and HCl (2.98 M solution în EtOAc, 240 ml) is dosed. The suspension is stirred for 1h at room température. The precipitate is filtered off, washed with acetone (100 ml) and suspended in a mixture of acetone (1.53 L) and EtOHabs. (180 ml) for 30 minutes at 50°C. The suspension is then cooled to 10°C and stirred for 30 minutes. The precipitate is filtered off, washed with cold acetone (200 ml) and dried intense to yield example 11 as dihydrochloride sait (117g, ee > 99.9 %, m.p.: 194 ± 5°C), optionally the product may also exists as hydrate of the dihydrochloride of example 11 without defîned melting point.
Synthesis of 2-amino-6,/V,/V-trimethylisonicotinamide
Step 1: 2-Chloro-6-methyl-isonicotinic acid [Lit.: Sperber et al., JACS 1959, 81, 704-707] (96.1 g) is suspended in toluene (480 ml) and DMF (0.5 ml) is added. After warming to 85°C SOCI2 (61.5 ml) is dosed. The reaction mixture is heated to reflux for 1,5h and then cooled to room température. After removal of solvent and excess reagent in vacuum, the residue is co-distilled with toluene (2 x 200 ml) and finally dissolved in toluene (300 ml). Afterwards, the above prepared solution is added to a mixture of Me2NH (2M solution in THF, 336 ml) and NEt3 (94 ml) at below 10°C. The mixture is warmed to room température and stirred for an additional 30 minutes. Water (300 ml) is added and the mixture is extracted with toluene (3 x 200 ml). The combined organic phases are washed with brine (1 x 200ml), dried over Na2SO4, filtered and evaporated. The oily residue is treated with n-heptane (288 ml) and seeds are added. After stirring 30 minutes at room température, the precipitate is filtered off, washed and dried in vacuum to yield intermediate 112 [93.7 g, m.p. : 85 ± 3°C, Rf = 0.22 (TLC, silica, ΡΕ/EtOAc = 1:1)].^
-2916358
Cl
112
Step 2: Intermediate 112 (26.7 g), Cs2CO3 (70 g), Pd(OAc)2 (302 mg) and (2Biphenyl)-di-tert.-butyiphosphin (0.92 g) are mixed in dioxaneabs. (270 ml) and benzyl amine (22.3 ml) is added. The reaction mixture is heated to 100°C over night, cooled to room température and filtered. Aqueous HCl (2M, 100 ml) is added and the mixture extracted with t-butylmethylether (70 ml). To the aqueous phase NaOH (4N, 55 ml) îs added. After extraction with tert-butylmethylether (3 x 70 ml) the combined organic phases are washed with brine, dried over Na2SO4, filtered and evaporated to dryness to yield intermediate 113 [23.0 g, m.p. : 124 ± 3°C, Rf = 0.20 (TLC, silica, ΡΕ/EtOAc = 2:3)].
O.
113
Step 3: Intermediate 113 (37.0 g) and Pd(OH)2/C are suspended in EtOHabs. (185 ml), and AcOH (16 ml). The mixture is hydrogenated at 70°C and 60psi until complété consumption. The mixture is filtered and the filtrate is evaporated to dryness. The remaining residue is dissolved in dichloromethane (250 ml), washed with Na2CO3-solution (10% in water, 150 ml) and dried over Na2SO4. After filtration and évaporation 2-amino-6,N,/\/-trimeÎhylisonîcotinamide 114 is isolated [22.2 g, m.p.: 168 ± 3°C, Rf = 0.15 (TLC, silica, deactivated with NEt3/PE, EtOAc)].
-3016358
Alternative: Intermediate 112 (26.6 g), CS2CO3 (48.9 g), benzophenonimine (25.0 g), Pd(OAc>2 (0.60 g) and racemic BINAP (4.52 g) are suspended in toluene (266 ml) and heated to 100°C for 2 days. The mixture is cooled to room température and filtered. 4N HCl (67 ml) is added to the filtrate und the mixture is stirred for 30 minutes at room température. Water (67 ml) is added and the phases are separated. The organic phase is extracted with water (50 ml). The combined aqueous phases are washed with toluene (100 ml). After addition of 4N NaOH (70 ml) the alkaline aqueous phase is extracted with CH2CI2 (4 x 100 ml). The combined organic phases are washed with brine (100 ml), dried over Na2SO4 and filtered. After évaporation to dryness, 2-amino-6,N,N-trimethylisonicotinamide 114 is isolated [22.1 g, Rf = 0.15 (TLC, silica, deactivated with NEt3/PE, EtOAc)].
Instead of benzyl amine (as in Step 1) or benzophenoimine (as in the Alternative) as described above further N-sources like CH3CONH2 oder CF3CONH2 can be used for the synthesîs of synthesîs of 2-amino-6,N,/V-trimethylîsonicotinamide.
Synthesîs of Examples via Method 4 (Exemplified with R1 is 3-methyl-4-chloro; R2a is cyclopropyl; R2b is Ν,Ν-dimethylcarboxamido; X is bromo and Y is methyl).
Step 1: To a stirred solution of I6 (90 mg) in THF (3 ml) at room température is added LiOH (10% aqueous solution; 0.05 mi). After 1h the reaction is heated to 30°C and after a further 30 min, concentrated under reduced pressure affording I9 (110 mg). HPLC (Rt) = 1.34 min (method D).
Step 2: To a stirred solution of I9 (80 mg) in dichloromethane (5 ml) containing a few drops of DMF at room température is added HATU (110 mg). After 45 min
-3116358 dimethylamine (0.014 ml) was added and the mixture stirred for 2 h. Additional HATU (110 mg) and dimethylamine (1 ml) are added and after 2 h the reaction is added to water/dichloromethane and phase separated via an Isolute HMN cartridge. The organic phase is dried under Na2SO4, filtered, and the solvent evaporated under reduced pressure. HPLC purification of the residue affords 110 (20 mg). HPLC (Rt) = 1.32 min (method D).
Step 3: To a stirred solution of bromocyclopropane (0.039 ml) in THF at -78°C under argon is added t-butyl lithium (0.056 ml) drop wise. After 25 min, cyclopropylzincbromide (0.5M in THF, 0.096 ml) is added and the mixture allowed to warm to rt. After 1 h 110 (23 mg) and 1,1’-bis (diphenylphosphino)ferrocenedichloropalladîum (II) (3 mg). After a further 35 min, further cyclopropylzincbromide (0.5M in THF, 0.096 ml) is added and 1 h later further cyclopropyl zinc bromide (0.5M in THF, 0.096 ml) added and the mixture stirred overnight. Further cyclopropyl zinc bromide (0.5M in THF, 0.24 ml) is added and after 4 h the mixture is diluted with THF and filtered. HPLC purification affords example 32 (7 mg). HPLC (Rt) = 1.34 min (method D).
Synthesis of Examples via Method 5 (Exemplified with R1 is 4-chloro-3-methyl; R2a is methoxy; R2b is Ν,Ν-dimethylcarboxamido; Y is methyl).
Step 1 : A solution of sodium methoxide (375 mg) and methyl 2,6 dibromoisonicotinate (1.0 g) in MeOH (20 ml) is heated in a microwave oven at 130°C for 30 min. Then additional sodium methoxide (281 mg) is added and heating continued for additional 15 min at 130°C. Concentrated sulphuric acid (1.86 ml) is then added to the reaction mixture and the resulting suspension is heated for 4 h at 80-85°C. After cooling to room température, the mixture is poured into an ice cold aqueous sodium carbonate solution (100 mL) and extracted with dichloromethane (100 ml). The organic layer is separated, dried over Na2SO4 and concentrated in vacuum. The residue is purified by MPLC (dichloromethane.MeOH = 100:3 to 100:5) to yield 710 mg of a 7:3 mixture of 2-bromo-6methoxyisonicotinate (497 mg) and the corresponding trimethyl citrazinic acid (213
-3216358 mg). HPLC (Rt) = 1.66 min (method D). This mixture is then used in a procedure analog to Step 2 în Method 1.
Steps 2+3: (Carried out analog to Steps 2,3 respectively in Method 2) Affords example 26 (7 mg). HPLC (Rt) = 1.29 min (method D).
Synthesis of Examples via Method 6 (Exemplified with R1 is 4-chloro-3-methyl; R2a is ethynyl; R2b is Ν,Ν-dimethylcarboxamido; X îs bromo; Y is methyl).
Step 1: To a solution of I6 (3.5 g) in THF (20 ml) at room température under argon is added TEA (2 ml), bistriphenylphosphinpalladiumchloride (219 mg) and copper(l)iodide (59 mg) followed by trimethylsilylacetylene (1 ml). After overnight stirring, the mixture was added to ice-water and extracted with EtOAc. The organic layer is separated, dried over Na2SO4 and concentrated in vacuum. Flash chromatography (95:5 dichloromethane:MeOH) affords 115 (3 g). Rf (95:5 dichloromethane:MeOH) 0.22.
Step 2: To a stirred solution of 115 (3 g) in dioxane (30 ml) at room température is added LiOH (1M aqueous solution, 10.4 ml). After 2 h, HCl (1M aqueous solution) is added to neutral pH and the résultant suspension is filtered and dried. HPLC purification affords 18 (with R2a is ethynyl) (2.3 g). HPLC (Rt) = 1.31 min (method D)
Step 3: (Carried out analog to Step 3 of Method 2).
Affords example 34 (210 mg). HPLC (Rt) = 1.23 min (method E)
The following examples can be synthesized according to the above methods:
-3316358
# Example | Structure | synth. Method | HPLC Method | HPLC Rt |
1 | °Y) N—/ \ λΧ >° Hf^ \w o | 2 | d | 1,24 |
2 | Yr ô~xr | 3 | b | 1,49 |
3 | ”Vr 0ΎΤ | 3 | b | 1,36 |
4 | o=\ A /0 ύΌ xy Y | 3 | B | 1,37 |
-3416358
# Example | Structure | synth. Method | HPLC Method | HPLC Rt |
5 | Y Y KM^NH Y | 3 | B | 1,50 |
6 | 7 \ to 0 Κl^^ Η’γΥ \ ''Ύ :nJ | 3 | D | 1,25 |
7 | /~Y to o oA /-f Y I. ΗΝγζ^Υ \ | 2 | d | 1,26 |
8 | °Y N—( \ Λ~ί >° Cl HVaJn“ | 2 | d | 1,22 |
-3516358
# Example | Structure | synth. Method | HPLC Method | HPLC Rt |
9 | Ύ) N—/ | 2 | D | 1,29 |
10 | °X) N—/ \ y \ Vv/ | 2 | d | 1,26 |
11 | “Ό N—? | 3 | d | 1,28 |
12 | °X) N—( | 2 | d | 1,32 |
13 | V) \ y \ λ=° /—o Cl | 2 | d | 1,24 |
-3616358
# Example | Structure | synth. Method | HPLC Method | HPLC Rt |
14 | XX.....f ÔY N xf | 3 | D | 1,27 |
15 | Y N—/ \ (A CIYY~/N~^ η^3υΥ> | 2 | D | 1,38 |
16 | 7 \ zo o JL HN<Y^ \x xX \ ,γ | 2 | B | 1,53 |
17 | 7 \ /0 □ Yf.....f , Χ-Μ JL \ 'Ύ \ X xf | 2 | B | 1,66 |
-3716358
# Example | Structure | synth. Method | HPLC Method | HPLC Rt |
18 | hnKÏ ) L J f—( AA \ F K | 2 | B | 1,60 |
19 | / \ ,o 0 0=< Λγ JL Ν' \ v | 2 | B | 1,65 |
21 | 7 \ ,o 0 ί/ \ K | 2 | B | 1,65 |
22 | K N—ί | 2 | D | 1,34 |
-3816358
# Example | Structure | synth. Method | HPLC Method | HPLC Rt |
23 | N—( | 2 | D | 1,36 |
24 | .....f0 v / ''''X \ Ά Br | 2 | d | 1,28 |
25 | 0. / J \ O ô’X X | 1 | d | 1,31 |
26 | o. / / \ /0 .....fi /=( x ôX X | 5 | d | 1,29 |
-3916358
# Example | Structure | synth. Method | HPLC Method | HPLC Rt |
27 | q. / 7 \ /0 V-N .....r=t X jy ' | 4 | d | 1,41 |
28 | J \ /0 0 °x >·.γ v il ‘/σ’ cr | 2 | d | 1,26 |
29 | o. / J~\ z° N\ oA/'f /=( X όσ A | 1 | d | 1,36 |
30 | J \ .0 q \ A | 3 | D | 1,21 |
-4016358
# Example | Structure | synth. Method | HPLC Method | HPLC Rt |
31 | 7 \ zo 0 °x ly F c ^0 \ 0 cr | 3 | D | 1,30 |
32 | o. / / \ /0 V~ N 00 0 cr | 4 | d | 1,34 |
33 | / \ /0 0 .....f 0-V ^0 \ 0 cr | 3 | D | 1,30 |
34 | o. / j \ o 0 0 \ 0 cr | 6 | e | 1,23 |
-4116358
# Exampïe | Structure | synth. Method | HPLC Method | HPLC Rt |
35 | / \ o o ό V Y | 3 | D | 1,31 |
36 | / \ ,O 0 '-'f L / ô Y Y | 2 | E | 1,24 |
EXAMPLES OF CO-CRYSTALS
Other features and advantages of the présent invention will become apparent from the following more detailed examples which illustrate, by way of example, the principles ofthe invention.
Synthesis of co-crystals starting from the dihydrochloride of compounds of formula 1 : Equimolar amounts of the dihydrochloride of one compound of formula 1, preferably one of the Examples 1 to 36 above, and the appropriate co-crystal former (selected from orotic acid, hippuric acid, L-pyroglutamic acid, Dpyroglutamic acid, nicotinic acid, L-(+)-ascorbic acid, saccharin, piperazine, 3hydroxy-2-naphtoic acid, mucic (galactaric) acid, pamoic (embonic) acid, stearic acid, cholic acid, deoxycholic acid, nicotinamide, isonicotinamide, succinamide, uracil, L-lysine, L-proline, D-valine, L-arginine, glycine) were combined în a proper
-4216358 solvent (chosen among e.g. 2-butanone, acetone, acetonitrile, isopropylacetate) at
80-50°C. After stirring 10-60 minutes the réaction mixture was cooied to room température, if needed additional solvent was added to facilitate the stirring of the mixture. Finally, the solid was recovered upon filtration, washed with a proper organic solvent and then dried in vacuum to yield the corresponding co-crystal.
Synthesis of co-crystals starting from the free base of compounds of formula 1: Equimolar amounts ofthefree base of one compound offormula 1, preferably one ofthe Examples 1 to 36 above, the appropriate co-crystal former (selected from orotlc acid, hippuric acid, L-pyroglutamic acid, D-pyroglutamic acid, nicotinic acid, L-(+)-ascorbic acid, saccharin, piperazine, 3-hydroxy-2-naphtoic acid, mucic (galactaric) acid, pamoic (embonic) acid, stearic acid, cholic acid, deoxycholic acid, nicotinamide, isonicotinamide, succinamide, uracil, L-lysine, Lproline, D-valine, L-arginine, glycine) and hydrochloric acid (1.5-2 equiv.) were combined in a proper solvent (chosen among e.g. 2-butanone, acetone, acetonitrile, isopropylacetate) and the mixture setto 80-50°C. After stirring 10-60 minutes the mixture was cooied to room température, if needed additional solvent was added to facilitate the stirrabîlîty of the mixture. Finally the solid was recovered upon filtration, washed with a proper organic solvent and then dried in vacuum to yield the corresponding co-crystal.
Analytics of exemplified co-crystals and salts
The crystalline co-crystal forms and salts were characterised by an X-ray powder diffraction pattern, made using CuKu] radiation, which comprises peaks at spécifie degrees 2© (±0.05 degrees 2Θ).
The X-ray powderdiffraction patterns are recorded, within the scope ofthe présent invention, using a STOE - STADI P-diffractometer in transmission mode fitted with a location-sensitive detector D(OED) and a Cu-anode as X-ray source (CuKal radiation, □ λ = 1,54056 A , 40kV, 40mA). '
-4316358
Table: 4 highest characteristic X-ray powder diffraction peaks for co-crystals obtained from Example 11 and the respective co-crystal former (ccf) used ccf ratio
Example 11 : ccf highest characteristic x-ray powder diffraction peaks 2-theta [°]
ascorbic acid | 1:0,5 | 10.75 | 16.04 | 17.26 | 19.41 |
mucic acid | 1:0.5-2 | 10.73 | 16.14 | 19.61 | 30.71 |
pamoic acid | 1:1.25 | 9.45 | 15.63 | 26.27 | 29.90 |
succinamide | 1:1-2 | 16.16 | 18.39 | 19.83 | 22.24 |
nicotinic acid | 1:1.1-1.2 | 6.29 | 14.64 | 18.71 | 26.66 |
nicotinamide | 1:1-1.1 | 14.68 | 18.58 | 24.11 | 26.51 |
isonicotinamide | 1:1-1.1 | 13.30 | 14.70 | 17.46 | 18.60 |
hydrated l-lysine | 1:0.8-1 | 11.32 | 14.69 | 18.61 | 21.99 |
hydrated l-lysine* | 1:0.8-1 | 13.30* | 23.98* | 24.62* | 31.45* |
l-proline | 1:1.1 | 16.39 | 17.69 | 18.71 | 21.55 |
‘hydrated l-lysine co-crystal obtained after dynamical vapour sorption -experiment of Ilysine co-crystal (exposure of rel. humidity in the range of 10-90%)
Table: 4 highest characteristic X-ray powder diffraction peaks for salts of example 11 (#Methyl-isobutyl-ketone)
sait | 4 highest characteristic x-ray powder diffraction peaks 2-theta [°] | |||
( S )-( S )-(+)-2,3-d ibenzoyl-ta rtrate | 3.72 | 13.60 | 16.89 | 19.34 |
dihydrochloride | 16.02 | 16.86 | 19.45 | 19.71 |
dihydrochloride*! 5H2O | 5.10 | 10.67 | 16.07 | 25.13 |
dihydrochloride*MIBK# | 5.08 | 15.97 | 16.81 | 18.56 J |
-4416358
PHARMACOLOGICAL PART
In another aspect, the instant invention may be used to evaluate the putative spécifie agonists or antagonists of a G protein coupled receptor. The présent invention is directed to the use of these compounds in the préparation and execution of screening assays for compounds that modulate the activity of chemokine receptors. Furthermore, the compounds of this invention are useful in establishing or determîning the binding site of other compounds to chemokine receptors, e.g,, by compétitive inhibition or as a reference in an assay to compare its known activity to a compound with an unknown activity. When developing new assays or protocole, compounds according to the présent invention could be used to test their effective ness.
Specifically, such compounds may be provided in a commercial kit, for example, for use în pharmaceutical research involving the aforementioned diseases. The compounds of the instant invention are also useful for the évaluation of putative spécifie modulators of the chemokine receptors. In addition, one could utiiize compounds of this invention to examine the specificity of G protein coupled receptors that are not thought to be chemokine receptors, either by serving as examples of compounds which do not bind or as structural variants of compounds active on these receptors which may help define spécifie sites of interaction.
The CCR3 receptor binding test is based on a K562 cell line (leukemia myelogenic blast cells) transfected with the human chemokine receptor CCR3 (hCCR3-C1 cells). The cell membranes were prepared by disrupting the hCCR3-C1 cells by nitrogen décomposition. The préparation was centrifuged at 400 g 4°C for 30 min. The supernatant was transferred into fresh tubes followed by a second centrifugation at 48000 g, 4°C for 1h. The membranes were re-suspended in the SPA incubation buffer (25mM HEPES, 25mM MgCI2 6xH20,1 mM CaCI2 2xH2O) without bovine sérum albumin and homogenized by passing through a single use needle (Terumo, 23Gx1”). The membranes were stored in aliquots at -80°C. o/'
-4516358
The CCR3 receptor binding assay was performed in a Scintillation Proximîty Assay (SPA) design with the radioligand recombinant human 125lodine-eotaxin-1. Cell membranes of hCCR3 C1 cells were again homogenized by passing through a single use needle (Terumo, 23Gx1”) and diluted in SPA incubation buffer in suitable concentrations (0.5 -10 pg protein/well) in 96 well microtiter plates (1450514, Perkin Elmer). The SPA assay was set up in the SPA incubation buffer with a final volume of 200pl and final concentration of 25mM HEPES, 25mM MgCI2 6xH2O, 1mM CaCI2 2xH2O and 0,1% bovine sérum albumin . The SPA assay mixture contained 60 pl ofthe membrane suspension, 80 pl ofWheat Germ Agglutinin coated PVT beads (organic scîntillator, GE Healthcare, RPNQ-0001 ) 0,2 mg/well), 40 pl of recombinant human 125Jodine-eotaxin-1 (Biotrend), diluted in SPA buffer to a final concentration of 30.000 dpm per well, and 20 pl of the test cornpound (dissolved in DMSO dilutions). The SPA assay mixture was incubated for 2 h at room température. Bound radioactivity was determined with a scintillation counter (Micro Beta Trilux, Wallac). Included were contrais for total binding (no displacer added, Bo) and non-specific binding (NSB) by adding unlabelled recombinant human Eotaxin-1 (Biotrend, Cat #300-21) or a reference cornpound.
Détermination of the affinity of a test cornpound was calculated by subtraction of the non-specific binding (NSB) from the total binding (Bo) or the binding in the presence ofthe test cornpound (B) at a given cornpound concentration. The NSB value was set to 100% inhibition. The Bo-NSB value was set to 0% inhibition.
The dissociation constant K, was calculated by itérative fitting of experimental data obtained at several cornpound concentrations over a dose range from 0.1 to 10000nM using the law of mass action based program easy sys (Schittkowski, Num Math 68, 129-142 (1994)).
The utility of the compounds in accordance with the présent invention as inhibitors of chemokine receptor activity may be demonstrated by methodology known in the art, such as the assays for CCR3 ligand binding, as disclosed by Ponath et al., J. νΛ
-4616358
Exp. Med., 183,2437-2448 (1996) and Uguccionî et al., J. Clin. Invest., 100,11371143 (1997). Cell linesfor expressing the receptor of interest include those naturally expressing the chemokine receptor, such as EOL-3 or THP-1, those induced to express the chemokine receptor by the addition of chemical or protein agents, such as HL-60 or AML14.3D10 cells treated with, for example, butyric acid with interleukin-5 présent, or a cell engineered to express a recombinant chemokine receptor, such as L1.2, K562, CHO or HEK-293 cells. Finally, blood or tissue cells, for example human peripheral blood eosinophils, isolated using methods as described by Hansel et al., J. Immunol. Methods, 145,105-110 (1991), can be utilîzed in such assays. In particular, the compounds of the présent invention hâve activity in binding to the CCR3 receptor in the aforementioned assays and inhibit the activation of CCR3 by CCR3 ligands, including eotaxin-1, eotaxin-2, eotaxin-3, MCP-2, MCP-3, MCP-4 or RANTES.
As used herein, activity is intended to mean a compound demonstrating an inhibition of 50% at 1 μΜ or higher in inhibition when measured in the aforementioned assays. Such a resuit is indicative of the intrinsic activity of the compounds as inhibitor of CCR3 receptor activity,
Ki values are (human Eotaxin-1 at human CCR3-Rezeptor):
# | hCCR3 Ki (nM) |
1 | 23,4 |
2 | 69,6 |
3 | 46,5 |
4 | 67,5 |
5 | 196,6 |
6 | 72,0 |
7 | 10,4 |
# | hCCR3 Ki (nM) |
8 | 8,5 |
9 | 0,9 |
10 | 6,0 |
11 | 3,2 |
12 | 4,7 |
13 | 19,1 |
14 | 1401,6 |
-4716358
# | hCCR3 Ki (nM) |
15 | 3,5 |
16 | 6,8 |
17 | 4,3 |
18 | 4,6 |
19 | 4,0 |
20 | 121,5 |
21 | 5,2 |
22 | 2,3 |
23 | 4,2 |
24 | 5,8 |
25 | 8,3 |
# | hCCR3 Ki (nM) |
26 | 231,6 |
27 | 413,8 |
28 | 17,8 |
29 | 4,1 |
30 | 70,3 |
31 | 87,2 |
32 | 2,3 |
33 | 7,9 |
34 | 7,9 |
35 | 61,3 |
36 | 1,7 |
INDICATIONS
The co-crystals and salts of the compounds of formula 1 as described above are useful for manufacturing a médicament for the prévention and/or treatment of diseases wherein the activity of a CCR3-receptor is involved.
Preferred is the manufacturing of a médicament for the prévention and/or io treatment of a wide variety of inflammatory, infectious, and immunoregulatory dîsorders and diseases ofthe respiratory or gastrointestinal complaints, inflammatory diseases of the joints and allergie diseases of the nasopharynx, eyes, and skîn, including asthma and allergie diseases, éosinophilie diseases, infection by pathogenic microbes (which, by définition, includes viruses), as well as autoimmune pathologies such as the rheumatoid arthritis and atherosclerosis, as well as diseases associated with abnormal enhanced neovascularization such as φ7'
-4816358 age-related macular degeneration (AMD), diabetic retinopathy and diabetic macular edema Age-related macular degeneration is a leading cause of blindness world wide. Most blindness in AMD results from invasion of the retina by choroidal neovascularization. CCR3 is specifically expressed in choroidal neovascular endothélial cells of AMD patients. In an often used mouse animal model for AMD laser injury-induced choroidal neovascularization was dimished by genetic déplétion of CCR3 or CCR3 ligands as well as by treatment of the mice with an antî-CCR3 antibody or an CCR3 antagonist (Takeda et al, Nature 2009, 460(7252):225-30)
Most preferred is the manufacturing of a médicament for the prévention and/or treatment of e.g. inflammatory or allergie diseases and conditions, including respîratory allergie diseases such as asthma, perennial and seasonal allergie rhinitis, allergie conjunctivitis, hypersensitivity lung diseases, hypersensitivity pneumonitis, éosinophilie cellulitis (e. g., Well's syndrome), éosinophilie pneumonias (e. g., Loeffler’s syndrome, chronic éosinophilie pneumonia), éosinophilie fasciitis (e. g., Shulman’s syndrome), delayed-type hypersensitivity, interstitial lung diseases (ILD) (e. g., idiopathic pulmonary fibrosis, or ILD associated with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome, polymyositis or dermatomyositis); non-allergie asthma; Exercise induced bronchoconstriction; systemic anaphylaxis or hypersensitivity responses, drug allergies (e. g., to penicillin, céphalosporine), eosinophilia-myalgia syndrome due to the ingestion of contaminated tryptophan, insect sting allergies; autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, immune thrombocytopenia (adult ITP, néonatal thrombocytopenia, paediatric ITP), immune haemolytic anaemia (auto-immune and drug induced), Evans syndrome (platelet and red cell immune cytopaenias), Rh disease of the newborn, Goodpasture’s syndrome (anti-GBM disease), Celiac, Auto-immune cardio-myopathy juvénile onset diabètes; glomerulonephritis, autoimmune thyroiditis, Behcet's disease; graft rejection (e.g., in transplantation), including allograft rejection or graftversus-host disease; inflammatory bowel o/”''
-4916358 diseases, such as Crohn's disease and ulcerative colitis; spondyloarthropathies; scleroderma; psoriasis (including Tcell mediated psoriasis) and infiammatory dermatoses such as an dermatitis, eczema, atopie dermatitis, allergie contact dermatitis, urticaria; vasculitis (e. g., necrotizing, cutaneous, and hypersensitivity vasculitis); erythema nodosum; éosinophilie myositis, éosinophilie fasciitis; cancers with leukocyte infiltration of the skin or organs; chronic obstructive pulmonary disease, age-related macular degeneration (AMD), dîabetic retinopathy and dîabetic macular edema.
METHOD OF TREATMENT
Accordingly, the présent invention is directed to co-crystals and salts of compounds of formula 1 as discribed above which are useful in the prévention and/or treatment of a wide variety of infiammatory, infectious, and immunoregulatory disorders and diseases, including asthma and allergie diseases, chronic obstructive pulmonary disease, infection by pathogenic microbes (which, by définition, includes viruses), autoimmune pathologies such as the rheumatoîd arthritis and atherosclerosis as well as age-related macular degeneration (AMD), dîabetic retinopathy and dîabetic macular edema.
For example a co-crystal or sait of an instant compound which inhibits one or more functions of a mammalian chemokine receptor (e. g., a human chemokine receptor) may be administered to inhibit (i. e., reduce or prevent) inflammation, infectious diseases or abnormal enhanced neovascularization. As a resuit, one or more infiammatory process, such as leukocyte émigration, adhesion, chemotaxis, exocytosis (e. g., of enzymes, growth factors, histamine) or infiammatory mediator release, survival or prolifération of CCR3 expressing cells is inhibited. For example, éosinophilie infiltration to infiammatory sites (e. g., in asthma or allergie rhinitis) can be inhibited according to the présent method. In particular, the cocrystal or sait of the following examples has activity in blocking the activation and migration of cells expressing the CCR3 receptor using the appropriate chemokines
-5016358 in the aforementioned assays. In another instance, endothélial prolifération and neovascularization may be inhibited (i. e., reduced or prevented). As a resuit abnormal enhanced neovascularization, i.e. of the retina, is inhibited.
In addition to primates, such as humans, a varîety of other mammals can be treated according to the method of the présent invention. For instance, mammals, including but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species can be treated. However, the method can also be practiced in other species, such as avîan species. The subject treated in the methods above is a mammal, male or female, în whom inhibition of chemokine receptor activity is desired.
Diseases or conditions of human or other species which can be treated with inhibitors of chemokine receptor function, include, but are not limited to: inflammatory or allergie diseases and conditions, including respiratory allergie diseases such as asthma, allergie rhînitis, hypersensitivity lung diseases, hypersensitivity pneumonîtis, éosinophilie cellulitis (e. g., Well's syndrome), éosinophilie pneumonias (e. g., Loeffler's syndrome, chronic éosinophilie pneumonia), éosinophilie fasciîtis (e. g., Shulman’s syndrome), delayed-type hypersensitivity, interstitial lung diseases (ILD) (e. g., idiopathic pulmonary fibrosis, or ILD associated with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome, polymyositis or dermatomyositis); chronic obstructive pulmonary disease (including rhinovirusinduced exacerbations); systemic anaphylaxis or hypersensitivity responses, drug allergies (e. g., to penicillin, cephalosporins), eosinophilia-myalgia syndrome due to the ingestion of contaminated tryptophan, insect sting allergies; autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, juvénile onset diabètes; glomerulonephritis, autoimmune thyroiditis, Behcet's disease; graft rejection (e. g., in transplantation), including allograft rejection or graftversus-host disease; inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis; spondyloarthropathies; scleroderma; psoriasis (including Tcell mediated psoriasis)
-5116358 and inflammatory dermatoses such as an dermatitis, eczema, atopie dermatitis, allergie contact dermatitis, urticaria; vasculitis (e. g., necrotizing, cutaneous, and hypersensitivity vasculitis); éosinophilie myositis, éosinophilie fasciitis; cancers with leukocyte infiltration of the skin or organs. Other diseases or conditions in which undesirable inflammatory responses are to be inhîbited can be treated, including, but not limited to, reperfusion injury, atherosclerosis, certain hématologie malignancies, cytokine-induced toxicity (e. g., septic shock, endotoxic shock), polymyositis, dermatomyositis. Infectious diseases or conditions of human or other species which can be treated with inhibitors of chemokine receptor fonction, include, but are not limited to, HIV.
Also diseases associated with abnormal enhanced neovascularization such as age-related macular degeneration (AMD), diabetic retinopathy and diabetic macular edema can be treated.
In another aspect, the instant invention may be used to evaluate the putative spécifie agonists or antagonists of a G protein coupled receptor. The présent invention is directed to the use of these compounds in the préparation and execution of screening assays for compounds that modulate the activity of chemokine receptors. Furthermore, the compounds of this invention are useful in establishîng or determining the binding site of other compounds to chemokine receptors, e. g., by compétitive inhibition or as a reference in an assay to compare its known activity to a compound with an unknown activity. When developing new assays or protocole, compounds according to the présent invention could be used to test their effective ness.
Specifically, such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving the aforementioned diseases. The compounds of the instant invention are also useful for the évaluation of putative spécifie modulators of the chemokine receptors. In addition, one could utilize compounds of this invention to examine the specificity of G protein coupled receptors that are not thought to be chemokine receptors, either by serving as Y
-5216358 examples of compounds which do not bind or as structural variants of compounds active on these receptors which may help define spécifie sites of interaction.
COMBINATIONS
The co-crystals and salts of compounds of formula 1 as described above may be used on their own or combined with other active substances of formula 1 according to the invention. The compounds of general formula 1 may optionally also be combined with other pharmacologically active substances. These include, B2-adrenoceptor-agonîsts (short and long-acting), anti-cholinergics (short and long-acting), anti-inflammatory steroids (oral and topical corticosteroids), cromoglycate, methylxanthine, dissociated-glucocorticoidmimetics, PDE3 inhibitors, PDE4- inhibitors, PDE7- inhibitors, LTD4 antagonists, EGFR- inhibitors, Dopamine agonists, PAF antagonists, Lipoxin A4 dérivatives, FPRL1 modulators, LTB4-receptor (BLT1, BLT2) antagoniste, Histamine H1 receptor antagonists, Histamine H4 receptor antagonists, dual Histamine H 1/H3-receptor antagonists, PI3-kînase inhibitors, inhibitors of non-receptor tyrosine kinases as for example LYN, LCK, SYK, ZAP-70, FYN, BTK or ITK, inhibitors of MAP kinases as for example p38, ERK1, ERK2, JNK1, JNK2, JNK3 orSAP, inhibitors ofthe NF-kB signalling pathway as for example IKK2 kinase inhibitors, iNOS inhibitors, MRP4 inhibitors, leukotriene biosynthese inhibitors as for example 5-Lipoxygenase (5LO) inhibitors, cPLA2 inhibitors, Leukotriene A4 Hydrolase inhibitors or FLAP inhibitors, Non-steroidale anti-inflammatory agents (NSAIDs), CRTH2 antagonists, DP1-receptor modulators, Thromboxane receptor antagonists, CCR3 antagonists, CCR4 antagonists, CCR1 antagonists, CCR5 antagonists, CCR6 antagonists, CCR7 antagonists, CCR8 antagonists, CCR9 antagonists, CCR30 antagonists, CXCR3 antagonists, CXCR4 antagonists, CXCR2 antagonists, CXCR1 antagonists, CXCR5 antagonists, CXCR6 antagonists, CX3CR3 antagonists, Neurokinin (NK1, NK2) antagonists, Sphingosine 1-Phosphate receptor modulators, Sphingosine 1 phosphate lyase inhibitors, Adenosine receptor modulators as for example A2aagonists, modulators of purinergic receptors as for example P2X7 inhibitors,
-5316358
Histone Deacetylase (HDAC) activators, Bradykinin (BK1, BK2) antagonists, TACE inhibitors, PPAR gamma modulators, Rho-kinase inhibitors, interleukin 1beta converting enzyme (ICE) inhibitors, Toll-Like receptor (TLR) modulators, HMG-CoA reductase inhibitors, VLA-4 antagonists, ICAM-1 inhibitors, SHIP agonists, GABAa receptor antagonist, ENaC-inhibitors, Melanocortin receptor (MC1R, MC2R, MC3R, MC4R, MC5R) modulators, CGRP antagonists, Endothelin antagonists, TNFa antagonists, anti-TNF antibodies, anti-GM-CSF antibodies, anti-CD46 antibodies, anti-IL-1 antibodies, anti-IL-2 antibodies, anti-IL-4 antibodies, anti-IL-5 antibodies, anti-IL-13 antibodies, antî-tL-4/IL-13 antibodies, anti-TSLP antibodies, antî-OX40 antibodies, mucoregulators, immunotherapeutic agents, compounds against swellîng of the airways, compounds against cough, VEGF inhibitors, but also combinations of two or three active substances.
Preferred are betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, CRTH2 inhibitors, 5-LO-inhibitors, Histamine receptor antagonists and SYK-înhibitors, but also combinations of two or three active substances, i.e.:
• Betamimetics with corticosteroids, PDE4-inhibitors, CRTH2-inhibitors or LTD4antagonists, • Anticholinergics with betamimetics, corticosteroids, PDE4-inhibitors, CRTH2inhibitors or LTD4-antagonists, • Corticosteroids with PDE4-inhibitors, CRTH2-inhibitors or LTD4-antagonists • PDE4-inhibitors with CRTH2-inhibîtors or LTD4-antagonists • CRTH2-inhibitors with LTD4-antagonists.
PHARMACEUTICAL FORMS
Suitable préparations for administering the co-crystals or salts of compounds of formula 1 include for example tablets, capsules, suppositories, solutions and powders etc. The content of the pharmaceutically active compound(s) should be in
-5416358 the range from 0.05 to 90 wt.-%, preferably 0.1 to 50 wt.-% ofthe composition as a whole. Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or algînic acid, binders such as starch or gélatine, lubricants such as magnésium stéarate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.
Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilitîes the core may also consist of a number of layers. Similarly the tablet coating may consist of a number or layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
Syrups or élixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillîn or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
Solutions are prepared in the usual way, e.g. with the addition of isotonie agents, preservatives such as p-hydroxybenzoates or stabilisera such as alkali métal salts of ethylenediaminetetraacetic acid, optionally using emulsifiers and/or dispersants, while if water is used as diluent, for example, organic solvents may optionally be used as solubilisera or dissolving aids, and the solutions may be transferred into injection vials or ampoules or infusion bottles.
-5516358
Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gélatine capsules.
Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the dérivatives thereof.
Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohois (e.g. éthanol or glycerol), carriers such as e.g. natural minerai powders (e.g. kaolins, clays, talc, chalk), synthetic minerai powders (e.g. highly dispersed sîlîcic acid and silicates), sugars (e.g. cane sugar, lactose and glucose), emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnésium stéarate, talc, stearic acid and sodium lauryl sulphate).
For oral use the tablets may obviously contain, in addition to the carriers specified, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additional substances such as starch, preferably potato starch, gélatine and the like. Lubricants such as magnésium stéarate, sodium laurylsulphate and talc may also be used to produce the tablets. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the abovementioned excipients.
For administering the co-crystals or salts of compounds of formula 1 it is particularly preferred according to the Invention to use préparations or pharmaceutical formulations which are suitable for inhalation. Inhalable préparations include inhalable powders, propellant-containing metered-dose aérosols or propellant-free inhalable solutions. Within the scope of the présent invention, the term propellant-free inhalable solutions also include concentrâtes or stérile inhalable solutions ready for use. The formulations which may be used ν’/' '
-5616358 within the scope of the présent invention are described in more detail in the next part of the spécification.
The inhalable powders which may be used according to the invention may contain a co-crystal or sait of 1 either on its own or in admixture with suitable physiologically acceptable excipients.
If the active substances 1 are présent in admixture with physiologically acceptable excipients, the following physiologically acceptable excipients may be used to préparé these inhalable powders according to the invention: monosaccharides (e.g. glucose orarabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextrans), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these excipients. Preferably, mono- or disaccharides are used, while the use of lactose or glucose is preferred, particularly, but not exclusively, in the form of their hydrates. For the purposes of the invention, lactose is the particularly preferred excipient, while lactose monohydrate is most particularly preferred.
Within the scope of the inhalable powders according to the invention the excipients hâve a maximum average particle size of up to 250 pm, preferably between 10 and 150 pm, most preferably between 15 and 80 pm. It may sometimes seem appropriate to add finer excipient fractions with an average particle size of 1 to 9 pm to the excipient mentioned above. These finer excipients are also selected from the group of possible excipients listed hereinbefore. Finally, in order to préparé the inhalable powders according to the invention, micronized active substance 1, preferably with an average particle size of 0.5 to 10 pm, more preferably from 1 to 5 pm, is added to the excipient mixture. Processes for producing the inhalable powders according to the invention by grinding and micronising and finally mixing the ingrédients together are known from the prior art.
-5716358
The inhalable powders according to the invention may be administered using inhalers known from the prior art.
The inhalation aérosols containing propellant gas according to the invention may contain a co-crystal or and sait of 1 dissolved in the propellant gas or in dispersed form. The co-crystals or and salts of 1 may be contained in separate formulations or in a common formulation, in which the co-crystals or salts of 1 are either both dissolved, both dispersed or in each case only one component is dissolved and the other is dispersed. The propellant gases which may be used to préparé the inhalation aérosols are known from the prior art. Suitable propellant gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as fluorinated dérivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The abovementioned propellant gases may be used on their own or mixed together. Particularly preferred propellant gases are halogenated alkane dérivatives selected from TG134a and TG227 and mixtures thereof.
The propellant-driven inhalation aérosols may also contain other ingrédients such as co-solvents, stabilisers, surfactants, antioxidants, lubricants and pH adjusters. Ail these ingrédients are known in the art.
The propellant-driven inhalation aérosols according to the invention mentioned above may be administered using inhalers known in the art (MDIs = metered dose inhalers).
Moreover, the active substances 1 according to the invention may be administered în the form of propellant-free inhalable solutions and suspensions. The solvent used may be an aqueous or alcoholic, preferably an ethanolic solution. The solvent may be water on its own or a mixture of water and éthanol. The relative proportion of éthanol compared with water is not limited but the maximum is preferably up to 70 percent by volume, more particularly up to 60 percent by volume and most preferably up to 30 percent by volume. The remainder of the —
-5816358 volume is made up of water. The solutions or suspensions containing a co-crystal or sait of 1 are adjusted to a pH of 2 to 7, preferably 2 to 5, using suitable acids. The pH may be adjusted using acids selected from inorganic or organic acids. Examples of particularly suitable inorganic acids include hydrochloric acid, s hydrobromic acid, nitric acid, sulphuric acid and/or phosphoric acid. Examples of particularly suitable organic acids include ascorbic acid, citric acid, malic acid, tartane acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and/or propionic acid etc. Preferred inorganic acids are hydrochloric and sulphuric acids. It is also possible to use the acids which hâve already formed an acid io addition sait with one of the active substances. Of the organic acids, ascorbic acid, fumaric acid and citric acid are preferred. If desired, mixtures of the above acids may be used, particularly in the case of acids which hâve other properties in addition to their acidifying qualifies, e.g. as flavourings, antioxidants or complexing agents, such as citric acid or ascorbic acid, for example. According to the invention, it is particularly preferred to use hydrochloric acid to adjust the pH.
If desired, the addition of editic acid (EDTA) or one of the known salts thereof, sodium edetate, as stabiliser or complexing agent may be omitted in these formulations. Other embodiments may contain this compound or these compounds. In a preferred embodiment the content based on sodium edetate is less than 100 mg/100ml, preferably less than 50mg/100ml, more preferably less than 20mg/100ml. Generally, inhalable solutions in which the content of sodium edetate is from 0 to 10mg/100ml are preferred. Co-solvents and/or other excipients may be added to the propellant-free inhalable solutions. Preferred co25 solvents are those which contain hydroxyl groups or other polar groups, e.g. alcohols - particularly isopropyl alcohol, glycols - particularly propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters. The terms excipients and additives in this context dénoté any pharmacologically acceptable substance which is not an 30 active substance but which can be formulated with the active substance or substances in the physiologically suitable solvent in order to improve the qualitative properties of the active substance formulation. Preferably, these
-5916358 substances hâve no pharmacologîcal effect or, in connection with the desired therapy, no appréciable or at least no undesirable pharmacologîcal effect. The excipients and additives include, for example, surfactants such as soya lecithin, oleic acid, sorbitan esters, such as polysorbates, polyvinylpyrrolidone, other stabilisers, complexing agents, antioxidants and/or preservatives which guarantee or prolong the shelf life of the finished pharmaceutical formulation, flavourings, vitamins and/or other additives known in the art. The additives also include pharmacologically acceptable salts such as sodium chloride as isotonie agents.
The preferred excipients include antioxidants such as ascorbic acid, for example, provided that it has not already been used to adjust the pH, vitamin A, vitamin E, tocopherols and similar vitamins and provitamins occurring in the human body.
Preservatives may be used to protect the formulation from contamination with pathogens. Suitable preservatives are those which are known in the art, particularly cetyl pyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate in the concentration known from the prior art. The preservatives mentioned above are preferably présent in concentrations of up to 50 mg/100 ml, more preferably between 5 and 20 mg/100 ml.
Preferred formulations contain, in addition to the solvent water and the co-crystal or sait of 1, only benzalkonium chloride and sodium edetate. In another preferred embodiment, no sodium edetate is présent.
The dosage of the compounds according to the invention is naturally highly dépendent on the method of administration and the complaint which is being treated. When administered by inhalation the compounds of formula 1 are characterised by a high potency even at doses in the pg range. The co-crystals or salis of compounds of formula 1 may also be used effectively above the pg range. The dosage may then be in the gram range, for example. S
-6016358
In another aspect the présent invention relates to the above-mentioned pharmaceutical formulations as such which are characterised in that they contain a co-crystal or sait of a cornpound of formula 1, particularly the above-mentioned pharmaceutical formulations which can be administered by inhalation.
The following examples of formulations illustrate the présent invention without restricting its scope:
EXAMPLES OF PHARMACEUTICAL FORMULATIONS
A) Tablets____________________per tablet
active substance 1 | 100 mg |
lactose | 140 mg |
maize starch | 240 mg |
polyvinylpyrrolidone | 15 mg |
magnésium stéarate | 5 mg |
500 mg
The finely ground active substance, lactose and some of the maize starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet granulated and dried. The granules, the remainîng maize starch and the magnésium stéarate are screened and mixed together. The mixture is pressed into tablets of suitable shape and size.
B) Tablets____________________per tablet active substance 1 80mg lactose 55mg maize starch190mg microcrystalline cellulose 35mg polyvinylpyrrolidone 15mg sodium carboxymethyl starch 23 mg
-6116358 magnésium stéarate 2 mg
400 mg
The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened. The sodium carboxymethyl starch and the magnésium stéarate are added and mixed in and the mixture is compressed to form tablets of a suitable size.
C) Ampoule solution active substance 150 mg sodium chloride50 mg water for inj.5 ml
The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make the solution isotonie. The resulting solution is filtered to remove pyrogens and the filtrate is transferred under aseptie conditions into ampoules which are then sterilised and heat-sealed. The ampoules contain 5 mg, 25 mg and 50 mg of active substance.
D) Meterînq aérosol_________________ active substance 1 0.005 sorbitan trioleate 0.1 monofluorotrichloromethane and TG134a : TG227 2:1 ad 100
The suspension is transferred into a conventional aérosol container with metering valve. Preferably 50 pl suspension are released on each actuation. The active substance may also be released in higher doses if desired (e.g. 0.02 wt.-%). qY'”
-6216358
E) Solutions (in mo/IQOml)___________ active substance 1 333.3 mg benzalkonium chloride 10.0 mg
EDTA 50.0 mg
HCI(1N) ad pH 2.4
This solution can be prepared in the usual way.
F)
Inhalable powder active substance 1 12 pg lactose monohydrate ad 25 mg
The inhalable powder is prepared in the usual way by mixing the individual ingrédients.
Claims (20)
- WHATWE CLAIM1. Co-crystals of compounds of formula 1 whereinR1 is C-i-e-alkyl, Cve-haloalkyl, O-Ci-e-haloalkyl, halogène;m is 1,2 or 3;R2a and R2b are each independently selected from H, C^alkyl, C^e-alkenyl, Ci-6-alkynyl, C^-cycloalkyl, COO-C^-alkyl, O-C^-alkyl, CONR2b 1R2b 2, halogène;R2b 1 is H, Cre-alkyl, C0.4-alkyl-C3.6-cycloalkyl, C^-haloalkyi;R2b 2 is H, Ci_6-alkyl;or R2b 1 and R2b2 are together a C3.6-alkylene group forming with the nitrogen atom a heterocyclic ring, wherein optionally one carbon atom or the ring is replaced by an oxygen atomR3 is H, Ci-e-alkyl;X is an anion selected from the group consisting of chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate,-6416358 benzoate, citrate, salicylate, fumarate, tartrate, dibenzoyltartrate, oxalate, succinate, benzoate and p-toluenesulphonate;j is 0, 0.5, 1, 1.5 or 2;with a co-crystal former selected from the group consisting of orotic acid, hippuric acid, L-pyroglutamic acid, D-pyroglutamic acid, nicotinic acid, L-(+)-ascorbic acid, saccharin, piperazine, 3-hydroxy-2-naphtoic acid, mucic (galactaric) acid, pamoic (embonic) acid, stearic acid, cholic acid, deoxycholic acid, nicotinamide, îsonicotinamide, succinamide, uracil, L-lysine, L-proline, D-valine, L-arginine, glycine.
- 2. Co-crystals of compounds of formula 1 according to claim 1, whereinR2a is H, Ci-e-alkyl, Ci.6-alkenyl, Ci-6-alkynyl, C3-6-cycloalkyl, O-Ci-6-alkyl, CONR2a,R2a2;R2a 1 is H, Ci-e-alkyl, Ci/-haloalkyl;R2a2 is H, Ci-6-alkyl;R2b is H, Ci-6-alkyl, Ci-6-alkenyl, Ci-e-alkynyl, C
- 3-6-cycloalkyl, COO-Ci-6-alkyl, OCi-e-alkyl, CONR2b 1R2b 2, halogène;R2b 1 is H, Ci.6-alkyl, C0-
- 4-alkyl-C3.6-cycloalkyl, Ci-6-haloalkyl;R2b 2 is H, Ci.6-alkyl;or R2b 1 and R2b 2 are together a C3-e-alkylene group forming with the nitrogen atom a heterocyclic ring, wherein optionally one carbon atom or the ring is replaced by an oxygen atom.-6516358
3. Co-crystals of compounds of formula 1 according to one of claims 1 or 2, wherein R1 is Cve-alkyl, Cve-haloalkyl, O-Ci.6-haloalkyl, halogène; m is 1 or 2; R2a is H, Ci-4-alkyl; R2b is H, CONR2b1R2b2; R2b·1 is C-M-alkyl, Co-4-alkyl-C3.6-cycloalkyl, Ci-4-haloalkyl; R2b·2 is H, CM-alkyl; or R2b 1 and R2b 2 are together a Ca.e-alkylene group forming with the nitrogen atom a heterocyclic ring, wherein optionally one carbon atom or the ring is replaced by an oxygen atom R3 is H, Ci.6-alkyl; X is an anion selected from the group consisting of chloride or dibenzoyltartrate j is 1 or 2. 4. Co-crystals of compounds of formula 1 according to one of claims 1 to 3, wherein R2a is H, Ci-4-alkyl; R2b is H, CONR2b 1R2b 2; -6616358R2b 1 is C-M-alkyl;R2b2 is CV4-alkyl. - 5. Co-crystals of compounds of formula 1 according to one of daims 1 to 4, whereinR2a is H, CM-alkyl;R2b îs H, CONR2b1R2b2;R2b1 is Co 4-alkyl-C:i.6-cycloalkyl;R2b2 is H, Ci_4-alkyl.
- 6. Co-crystals of compounds of formula 1 according to one of daims 1 to 5, whereinR2a is H, C^-alkyl;R2b is H, CONR2b 1R2b 2;R2b 1 is C14-haloalkyl,·R2b2 is H, Cn-alkyl.
- 7. Co-crystals of compounds of formula 1 according to one of daims 1 to 6, wherein R2b 1 and R2b 2 are together a C3-6-alkylene group forming with the nitrogen atom a heterocyclic ring, wherein optionally one carbon atom or the ring is replaced by an oxygen atom.-6716358
- 8. Co-crystals of compounds of formula 1 according to one of claims 1 to 7, wherein the co-crystal former is selected from the group consisting of ascorbic acid, mucic acid, pamoîc acid, succinamide, nicotinic acid, nicottnamide, isonicotinamide, l-lysine, l-proline, or hydrates or hydrochlorides of the same.
- 9. Salts of compounds of formula 1, wherein R1, m, R2a, R2b, R3 are defined as in one of claims 1 to 8 andX is an an ion selected from the group consisting of chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, fumarate, tartrate, dibenzoyltartrate, oxalate, succinate, benzoate and p-toluenesulphonate;j is 0, 0.5, 1, 1.5 or 2.
- 10. Salts of compounds of formula 1, wherein R1, m, R2a, R2b, R3 are defined as in one of claims 1 to 8 andX is an anion selected from the group consisting of chloride or dibenzoyltartrate i is 1 or 2.
- 11.
- 12.Salts according to claim 9 or 10 used for the manufacture of a co-crystal according to one of claims 1 to 8.Compounds of formula 112 for the manufacture of a co-crystal or a sait of formula 1 according to one of claims 1 to 11.112
- 13.Compounds of formula 113 for the manufacture of a co-crystal or a sait of formula 1 according to one of claims 1 to 11.
- 14.Compounds of formula 114 for the manufacture of a co-crystal or a sait of formula 1 according to one of claim 1 to 11.-6916358114
- 15. Compounds of formula I3’-Me for the manufacture of a co-crystal or a sait of s formula 1 according to one of claim 1 to 11.io
- 16. Compounds of formula 14' for the manufacture of a co-crystal or a sait of formula 1 according to one of claim 1 to 11.
- 17. Compounds of formula A’ for the manufacture of a co-crystal or a sait of formula 1 according to one of claim 1 to 11.-7016358
- 18, A pharmaceutical composition comprising at Ieast one co-crystal or sait of a compound of formula 1 according to any one of claims 1 to 14 and a pharmaceutically acceptable carrier.
- 19. A co-crystal or sait of a compound of formula 1, according to one of claims 1 to 10, as a médicament.
- 20. Use of a co-crystal or sait of a compound of formula 1, according to one of claims 1 to 10, for the prévention or treatment of a wide variety of inflammatory, infectious, and immunoregulatory disorders and diseases, including asthma and allergie diseases, chronic obstructive pulmonary disease, infection by pathogenic microbes (including viruses), autoimmune pathologies such as the rheumatoid arthritis and atherosclerosis as well as age-related macular degeneration (AMD), diabetic retinopathy and diabetic macular edema.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10186901.4 | 2010-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA16358A true OA16358A (en) | 2015-05-11 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2625174B1 (en) | Co-crystals and salts of ccr3-inhibitors | |
USRE45323E1 (en) | Substituted piperidines as CCR3 antagonists | |
OA16358A (en) | Co-crystals and salts of CCR3-inhibitors. | |
OA16376A (en) | Modular storage and handling device for a plurality of flexible pipes. |